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Chapter 1: Systematic Review 
 
 
 
 
Is growth hormone treatment associated with psychological outcomes in girls with Turner Syndrome? A 
systematic review. 
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Abstract 
Purpose 
Growth hormone treatment (GHT) is a widely accepted intervention to increase adult height in girls with 
Turner Syndrome (TS). However, the impact of GHT on psychological outcomes in girls with TS remains 
unclear. This review aimed to systematically evaluate the research literature on TS girls treated with GH, 
to explore whether there are any associations with psychological outcomes.  
Methods 
A systematic search of five electronic databases was conducted to identify relevant studies. Following 
this, 2,823 studies were screened and fourteen met the inclusion criteria for this review. A narrative 
synthesis of the findings was conducted.  
Results 
To date, literature exploring whether there are any associations between GHT and psychological 
outcomes in girls with TS has predominantly focused on Quality of Life/Health-Related Quality of Life 
or Psychosocial Functioning. The results indicate there could be a small positive association between 
GHT and some psychological outcomes, however findings were inconsistent and variable across studies. 
Several factors such as the study design and various methodological limitations and biases may explain 
some of the variability within the results. 
Conclusions 
There does not appear to be any definitive association between GHT and psychological outcomes in girls 
with TS. Therefore, height enhancement alone should be used as the primary measure to determine 
whether girls with TS receive GHT.  
 
Keywords: Turner Syndrome, growth hormone therapy, psychological outcomes, systematic review 
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Introduction  
Turner Syndrome 
Turner Syndrome (TS) is a relatively common genetic condition which affects between approximately 
1/2000 and 1/2500 live female births (Stochholm et al., 2006; Apperley et al., 2018). The condition is 
caused by the absence of all or part of the second sex chromosome. Women with TS typically present 
with shorter stature, cardiovascular, reproductive, renal, endocrine, vision and/or hearing abnormalities 
(Morgan, 2007; Bondy, 2014).  
Individuals with TS may develop severe medical conditions such as epilepsy and have increased mortality 
rates (Power, Langlois and Byard, 2014). Moreover, females with TS appear to demonstrate a unique 
cognitive profile, characterised by weaknesses in executive functioning and visual-spatial areas and 
relative strengths in verbal domains (Hong, Scaletta Kent and Kesler, 2009). Due to the variability in 
clinical manifestations, the age at which girls receive a diagnosis is widely variable, from the second 
trimester of pregnancy, through to adulthood (Apperley et al., 2018). 
Short Stature and Growth Hormone Therapy 
Short Stature (SS), one of the most prevalent and salient features of TS, is statistically defined in the 
current literature as height more than 2 standard deviations below the mean for gender and age specific 
norms (Tanner and Whitehouse, 1976). Individuals with SS are treated by supplementing or replacing a 
missing or insufficient hormone, to allow for expected growth and to improve general health. The Food 
and Drug Administration in the USA approved recombinant human growth hormone (rhGH) in 1985 to 
accelerate growth and increase height in conditions not typically associated with growth hormone 
deficiency, including TS (Gault and Donaldson, 2001). A systematic review assessing the effects on 
children and adolescents with TS concluded that rhGH increased short-term growth by approximately 
three to six cm compared to untreated control groups (Baxter et al., 2007). However, the final height of 
the participants was still below normal range.  
The rationale for growth hormone treatment (GHT) traditionally rests on the belief that SS constitutes a 
psychosocial or psychoeducational vulnerability, or burden for the individual (Gardner et al., 2016). As 
well as accelerated growth and increased adult height, an underlying assumption was that GHT would 
lead to improved psychosocial adaptation and quality of life (Siegel, Clopper and Stabler, 1998). An 
increased growth velocity may therefore reduce the “at-risk” status of these individuals for developing 
psychosocial adjustment difficulties in adulthood (Meyer-Bahlburg, 1990).  
Psychological outcomes in females with TS 
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Alongside the physical health problems and cognitive deficits previously described, several studies 
suggest girls with TS may experience difficulties with mood, relationships and psychosocial functioning 
(Cardoso et al., 2004; Rolstad et al., 2007; Reimann et al., 2018). Liedmeier et al. (2020) found women 
with TS aged 16-73 years reported impairments across a number of psychosocial variables in comparison 
to healthy controls, including QoL, depression, anxiety, self-esteem, social participation and romantic 
relationships.  A systematic review similarly found that QoL appears to be compromised in women with 
TS (Reis et al., 2018). The researchers suggest the reduction in QoL could be related to factors such as 
height, however the results were inconclusive.  
Consistent with previous research, it could thus be assumed that GHT and a subsequent increase in height 
may be positively associated with psychological outcomes in girls with TS. However, the evidence base 
appears somewhat variable. After 18 months, TS girls randomised to GHT reported significantly better 
social relationships and self-concept in comparison to an untreated control group (Rovet and Holland, 
1993). However, after six years of GHT, the researchers found no global differences across all 
psychosocial functioning domains measured (Rovet et al., 2019). Moreover, a systematic review which 
examined the effects of GHT on psychological outcomes in individuals with SS concluded there is a high 
risk of bias present in the majority of the literature (Gardner et al., 2016). This review focused on 
individuals with a range of conditions resulting in SS, rather than focusing on females with TS 
exclusively. It is therefore unclear whether there are any positive or negative associations between GHT 
and psychological outcomes in girls with TS, and whether the current literature is similarly at a high risk 
of bias.  
Aims  
To our knowledge, no systematic review has been conducted to specifically examine whether GHT is 
associated with psychological outcomes in girls with TS. The aim of this review, therefore, is to 
systematically evaluate the research literature on TS girls treated with GH, to explore whether there are 
any associations with psychological outcomes.  
 
Methods  
Search strategy  
Psychological outcomes have been defined as quality of life, psychological adjustment/adaptation, 
psychosocial functioning, mood, well-being and emotional/behavioural outcomes. There does not appear 
to be a standardised definition of ‘psychological outcomes’ within current literature, and so our definition 
is based on previous analogous research (Broadstock, Michie and Marteau, 2000; Gardner et al., 2016). 
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Prior to conducting the search, the search strategy was discussed and agreed with the author’s academic 
supervisor and a University librarian. Full details of the search strategy can be found in Appendix 1.2. 
Variations of the following terms were used: 
 
1. Turner Syndrome 
AND 
2. Growth Hormone Therapy 
AND 
3. Psychological outcome or psychosocial outcome or adaptation, psychological or emotional 
adjustment or social adjustment or quality of life or mental disorder or affective symptoms or 
mental health or anxiety or depression or well-being  
 
The following electronic databases were searched on 23/04/20: CINAHL (1982-Present), Ovid Embase 
(1947-Present), Ovid MEDLINE (1946-Present), PsycINFO (1806-Present) and Web of Science (1864-
Present). Citations that appeared potentially relevant from the reference list of full texts screened were 
also considered for inclusion. The search strategy used both text words and relevant indexing, and search 
terms were adapted to map onto subject headings where relevant. The results were exported to EndNote. 
The study was also registered on PROSPERO (registration no: CRD42019159559) 
 
Inclusion/exclusion criteria  
Inclusion: 
• Quantitative studies (both randomised and non-randomised trials) or qualitative studies  
• Studies which include females diagnosed with TS AND; 
• Participants have been prescribed GHT 
• Studies which examined the association between GHT and psychological outcomes, as defined 
above  
• Children, adolescent and adult females with a diagnosis of TS 
Exclusion: 
• Reviews or case studies  
• Studies that are not written in English  
9 
 
Following the removal of duplicates, titles and abstracts were screened by the author to identify studies 
that did not meet the inclusion criteria. Full text versions of the remaining articles were reviewed for 
eligibility and included if all criteria were met. A PRISMA four-phase diagram was produced (Figure 1).  
Figure 1. PRISMA flow-chart diagram  
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Data Extraction and Quality rating   
A data extraction sheet was constructed (Appendix 1.3) in line with PRISMA guidelines on data 
extraction (Liberati et al., 2009). The Crowe Critical Appraisal Tool (CCAT) (Crowe and Sheppard, 
2011) was used to assess the quality of the included full texts as the author anticipated that the data and 
results would be heterogeneous in nature (Appendix 1.4). Therefore, the CCAT was chosen as it can be 
used across a variety of research designs. Four (35%) of the full texts identified were reviewed by a 
second, independent rater (trainee clinical psychologist), to ensure consistency in quality rating. One 
discrepancy was discussed until an agreement was reached.  
 
Results  
Study characteristics  
Details of the sampling and methods for each of the fourteen included studies can be found in Table 1. 
Four of the studies are randomised-controlled trials (RCTs) and the remaining ten are non-randomised. 
All participants with TS in the included studies were treated with GHT in accordance with standardised 
guidelines (Bondy, 2009).  
With regards to the psychological outcomes measured, seven studies explored Quality of Life (QoL) or 
Health-Related Quality of Life (HRQoL) (Study no. 4,5,6,7,8,9,12), six studies measured Psychosocial 
Functioning (Study no. 1,2,3,10,11,14) and one study examined ‘Psychological profile’ defined as 
intelligence, social competence and behaviour problems (Study no. 13). Several studies included 
secondary outcome measures including body image, self-concept, perception of stature and height. Three 
RCTs included an untreated TS group as the control condition, whilst six of the non-randomised studies 
used population control groups. Three studies had no control group and two included a population-based 
control group and control groups of participants with other conditions resulting in short stature e.g. 
idiopathic GH deficiency.  
Quality of the studies 
The maximum score a study could achieve is 40; quality appraisal scores ranged from 19 (48%) to 33 
(83%). The quality of the papers was generally moderate; studies often failed to detail their sample size 
calculations or control for confounding variables.  
 
 
11 
 
Table 1. Study Characteristics and Key Findings 
Study  
No. 
Author, Year, 
Country 
Design  Sample 
characteristics  
Intervention Psychological 
outcome  
Measures used Key Findings Quality 
rating score 
1 Rovet et al., 
1993  
Canada 
 
 
 
 
 
RCT  N=48 
28 treated TS girls 
(mean age 10.8) 
20 untreated TS girls 
(mean age 10.7)  
 
GHT for 18 months. 
All participants given 
oestrogen therapy at 
13 years old. 
Self-Concept 
Family functioning  
Behaviour, social 
abilities and school 
functioning  
Piers-Harris Children’s 
Self-Concept Scale 
(PHCSCS) (Piers, 1969) 
Youth Self-report (YSR) 
(Achenbach, 1991b) 
Child Behaviour Checklist 
(CBC) (Achenbach, 
1991a) 
Olson’s FACES III (Olson, 
1986) 
Prospectively, GH treated girls self-
reported themselves as significantly 
more intelligent, attractive, having 
better self-concept, more friends, 
greater popularity and less teasing 
in comparison to untreated controls.  
No differences in behaviour other 
than hyperactivity which showed a 
greater decrease with time in 
untreated group. 
28 (70%) 
2 Rovet et al., 
2019 
Canada  
RCT  N=131 
70 treated TS girls  
61 untreated TS girls 
(Session 1 mean age 
10.4 - Session 4 
mean age 16.3) 
GHT for 6 years. 
Majority of patients 
received oestrogen 
therapy. 
Psychosocial 
functioning  
 
PHCSCS 
YSR 
CBC 
No global group differences 
between treated and untreated girls 
were found on any scales or 
subscales across the four 
psychosocial functioning domains. 
33 (83%) 
3 Huisman et al., 
1993 
Netherlands  
 
RCT  N=38 girls with TS 
(mean age at entry 
12.2. At T3 mean age 
14.6) 
Participants were 
randomly assigned to 
one of two dose 
regimens: GH, 8 
HJ/m2 body surface 3 
times/week and GH. 
4 HJ/m2 6 
times/week. 
Participants over 12 
years old received 
ethinyl oestradiol. 
 
 
Psychosocial 
functioning  
PHCSCS 
CBC 
The Social Anxiety Scale 
for children (La Greca et 
al., 1988) 
The Silhouette 
Apperception Technique 
(Child and Parent Version) 
(Grew et al., 1983) 
The Therapy Evaluation 
Scale (Child and Parent 
Version)  
Parental Interview 
Teacher rating form (Keith 
Conners et al., 1998) 
Post GHT girls and their parents 
reported increased independence, 
happiness and more involvement in 
social interactions. No significant 
changes in self-concept, social 
anxiety, or behavioural problems 
were found.  
20 (50%) 
4 Taback et al., 
2011 
Canada 
RCT  N=33 
From the Canadian 
RCT. 
21 treated TS girls 
(mean age 20.0) 
GHT for 6 years. 
Majority of patients 
received oestrogen 
therapy. 
Health related quality 
of life  
Short Form-36 Health 
Survey (SF-36) (Ware and 
Sherbourne, 1992) 
 
No differences between treated and 
untreated controls or the general 
population, indicating neither 
benefits nor adverse effect of GHT 
on HRQoL in females with TS.  
 
29 (73%) 
12 
 
12 TS girls from the 
untreated group, 
however only 10 had 
never had GHT 
(mean age 20.2) 
5 Amundson et 
al., 2010 
Sweden  
Cross-
sectional, 
case 
controlled  
N=222 
111 TS women (age 
range 18–59)  
111 randomly 
selected, age 
matched women (25–
54)  
GH and Oxandrolone 
treatment were given 
to 45(40%) 
GH only to 13(12%) 
Oxandrolone only to 
19(17%) 
Neither GH nor 
oxandrolone had 
been given to 35 
(31%) TS women. 
Quality of Life The Psychological General 
Well-being Index 
(PGWBI) (Dupuy, 1984)  
The Nottingham Health 
Profile (NHP) (McEwen, 
1993) 
 
TS women reported more social 
isolation than population controls. 
Untreated TS women reported more 
sleeping problems and social 
isolation in comparison to GH 
treated women. After adjustment 
for age, pain remained the only 
variable significant and attributable 
to GHT.  
23 (58%) 
6 Bannick et al., 
2006 
Holland  
Cross-
sectional 
case 
controlled  
N = 165 
49 girls with TS 
116 general 
population controls 
(Mean age 19.4) 
34 had GHT once 
daily at a dose of 1.3, 
2, or 2.7 mg/m2 body 
surface area/day 
(∼0.045, 0.067, or 
0.09 mg/kg/day).  
15 had GHT once or 
twice daily in a dose 
of 2 mg/m2 body 
surface area/day 
(∼0.067 mg/kg/day). 
Participants also 
received ethinyl 
oestradiol. 
Health-related 
Quality of Life 
SF-36 
TNO/AZL Adult Quality 
of Life (TAAQOL) 
(Kamphuis et al., 2004) 
 
Women with TS reported 
significantly better social 
functioning, role limitations– 
emotional, bodily pain, daily 
activities, sexuality, and aggressive 
emotions in comparison to 
population controls. No other 
differences were observed.  
23 (58%) 
7 Butler et al., 
2019 
UK 
Prospective 
one year 
controlled  
73 = IGHD 
45 = AGHD 
22 = TS 
49 = controls with 
non GHD short 
stature 
(aged 6-16)  
GHT Health Related 
Quality of Life  
Paediatric Quality of Life 
Inventory (Upton et al., 
2005) 
Strengths and Difficulties 
Questionnaire (Goodman, 
1997) 
The Youth Life 
Orientation Test Revised 
(Ey et al., 2005) 
All measures evaluated showed an 
equal improvement over the year of 
GHT, across all groups. After 12 
months, the untreated SS controls 
and TS group scored higher than 
UK norms. 
30 (75%) 
8 Carel et al., 
2005 
France 
Population-
Based cohort 
study  
N=568 treated TS 
girls (Mean age 22.6) 
GHT Quality of life and its 
determinants  
SF-36 
General Health 
Questionnaire 12 (GHQ-
12) (Goldberg, 1972) 
QoL scores were similar between 
GH treated women with TS and the 
general population.  
27 (68%) 
13 
 
9 Krantz et al., 
2019 
Sweden 
Longitudinal 
cohort study 
N=228 treated TS 
girls  
N=317 controls 
(randomly selected 
population-based 
sample) 
(aged 16-78) 
GHT Health-related 
Quality of Life 
PGWBI 
NHP 
No associations were found 
between HRQoL and GHT in 
women with TS and there were no 
differences between participants 
and the general population. 
30 (75%) 
10 Lagrou et al., 
1998 
Belgium  
 
Descriptive 
non-
randomised  
N=31 girls with TS 
A: 3-6 years 
B: 7-12 years 
C: 13-16 years 
GHT 
6 engaged with 
oestrogen treatment 
after 1 year of 
therapy.  
Perception of stature 
Psychosocial 
functioning  
CBC 
YSR 
Self-esteem Inventory 
(Coopersmith, 1984) 
Observation of play and 
semi-structured interviews 
with both girl and parents 
Following GHT girls reported no 
changes in psychosocial 
functioning other than 
improvements in social self-esteem 
and social competence. The 
researchers found some differences 
in perception of height and 
acceptance of GHT between age 
groups.  
22 (55%) 
11 Lagrou et al., 
2006 
Belgium  
Cross-
sectional 
case 
controlled 
N=74 
30 treated TS girls 
(mean age 22.1) 
44 aged matched 
controls (mean age 
20.5) 
GHT 
Some participants 
received oestrogen 
therapy.  
Psychosocial 
functioning 
(behavioural and 
emotional problems) 
Self-concept 
Body image  
Young Adult Self Report 
(Achenbach, 1997) 
Self-Perception Profile for 
College Students (Harter 
and Neemann, 1986) 
Bodily Attitude Scale 
(BAS) (Simis, Verhulst 
and Koot, 2001) 
Following GHT, in comparison to 
population controls, women with 
TS reported no significant 
differences other than more 
attentional difficulties and 
perceiving themselves as less 
socially competent. The TS group 
reported fewer problems in some 
subscales including fewer 
delinquent behaviours and somatic 
complaints.  
23 (58%) 
12 Lasaite, 
Lasiene and 
Lasas, 2010  
Lithuania  
Cross-
sectional, 
case-
controlled  
N=57 
18 = treated TS girls 
(mean age 21.5) 
39 = age/sex 
matched controls 
GHT for at least five 
years. 
Some participants 
received hormone 
replacement therapy.  
Cognition, Emotions 
and Quality of Life 
Profile of mood states 
(POMS) (McNair, Lorr 
and Droppleman, 1992) 
Quality of Life 
Assessment of GH 
Deficient Adults (Holmes 
et al., 1995) 
After GHT discontinuation, women 
with TS reported significantly 
higher Tension-anxiety, depression-
dejection and cognitive functioning 
(suggesting worse psychometric 
speed) than controls. Vigour-
activity and QoL were significantly 
lower compared to controls.  
19 (48%) 
13 Siegel, 
Clopper & 
Stabler, 1998 
US 
Longitudinal 
cohort  
N=429 
146 = children of 
normal stature 
matched for age, sex 
and socioeconomic 
status (control) 
37 = girls with TS 
GHT for three years Psychological profile: 
Intelligence  
Social competence 
and behaviour 
problems  
CBC 
The Wide Range 
Achievement Test 
The Slosson Intelligence 
Test (Hammill, 1968) 
Over three years of GHT girls with 
TS reported significant decreases in 
attention, social problems, and 
withdrawal. No differences in IQ or 
achievement scores.  
24 (60%) 
14 
 
27 = girls with 
isolated growth 
hormone deficiency  
24 = girls with 
idiopathic short 
stature 
14 Van Pareren et 
al., 2005 
Holland  
Cross-
sectional 
case-
controlled 
N=50 
36 = treated TS girls 
from dose response 
study (mean age 
18.2) 
14 = treated TS girls 
from frequency 
response study (mean 
age 20.4) 
359 = normal 
population control 
(mean age 17.1) 
GHT 
Hormone 
replacement therapy. 
Psychosocial 
functioning 
(behavioural 
problems, self-
perception, 
depression, body 
image, family 
functioning, coping) 
YASR 
Harter Self-Perception 
Profile (Harter, 1985) 
Child Depression 
Inventory (Kovacs, 1992) 
BAS 
Family Assessment Device 
(Byles et al., 1988) 
Utrecht Coping List 
(Bijstra, Jackson and 
Bosma, 1994) 
After reaching final height 
following GHT, women with TS 
reported no significant differences 
in behavioural problems or 
depression in comparison to 
controls. Self-perception and bodily 
attitude were significantly lower 
than the normal population, 
however family functioning was 
rated higher.  
24 (60%) 
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Narrative Synthesis 
This review provides a narrative synthesis of findings from included studies, structured around the 
psychological outcome explored and study design.  
Quality of Life/Health Related Quality of Life 
Randomised-Controlled Trials 
Taback and Van Vliet (2011) measured HRQoL post GHT in a group of untreated and treated 
participants; the researchers found no differences in scores between the treatment groups and similar 
scores to norms of females within the general population.  
Non-randomised Studies  
Carel et al. (2005) evaluated the determinants of QoL in GH treated young women with TS; there were 
no significant differences in scores between participants and the general female population. A 20-year 
longitudinal study comparing HRQoL in TS females to that of the general population indicated HRQoL 
was not significantly associated with GHT, despite a mean 5.7cm increase in height (Krantz et al., 2019). 
There were no significant differences between the groups at baseline and follow-up.  
A cross-sectional case-controlled study compared QoL in females with TS to randomly selected, age-
matched controls (Amundson et al., 2010). After adjustment for age in a logistic regression analysis, with 
GHT as the dependent variable, only less physical pain remained significant and attributable to GHT. TS 
women without GHT reported more social isolation compared with controls. The Bannink et al. (2006) 
study compared HRQoL in GH treated young women with TS to a general population control group, post 
intervention. There were no statistically significant differences between scores, other than a small number 
of domains including social functioning and bodily pain, where the TS group reported significantly higher 
scores.  
Following a prospective one year controlled study, girls with TS reported an improvement in HRQoL 
across all measures, and higher scores than UK norms (Butler et al., 2019). However, there were no 
statistically significant differences in scores between TS and SS controls. Lastly, Lašaite, Lašiene and 
Lašas (2010) reported significantly higher tension-anxiety and depression-dejection scores and 
significantly lower QoL scores following GHT discontinuation in a TS group compared to age/sex 
matched controls.  
Overall, 3/7 studies found no associations between GHT and QoL/HRQoL in girls with TS (Carel et al., 
2005; Taback and Van Vliet, 2011; Krantz et al., 2019). Two studies reported no significant differences 
aside from a small number of subscales including pain and social functioning, in which TS girls reported 
significantly better scores compared to population  controls (Bannink et al., 2006; Amundson et al., 
16 
 
2010). One study reported improvements across all HRQoL measures following one year of GHT (Butler 
et al., 2019), whilst Lašaite, Lašiene and Lašas (2010) reported significantly lower QoL in GH treated 
girls in comparison to controls.  
Psychosocial functioning  
Randomised-Controlled Trials 
Rovet and Holland (1993) compared psychological functioning in girls with TS randomised to either a 
GHT group or an untreated control group. After 18 months, girls in the treated group reported 
significantly higher scores in self-concept and social relationships. Rovet et al. (2019) completed a 
longitudinal sub-study of the original RCT; after 6 years of GHT the researchers found no global 
differences across the four domains measured.  
A third RCT measured psychosocial functioning in girls with TS randomised to one of two dose regimes, 
before and after two years of GHT (Huismen, 1993). The results showed no significant changes in social 
anxiety, self-concept or behavioural problems. Both girls and their parents self-reported an improvement 
in independence, happiness and social interaction.  
Non-randomised Studies  
In a group of girls with TS, over two years of GHT, researchers found no significant changes in scores, 
other than an improvement in social competence for 7-12 and 13-16 year olds, and general/social self-
esteem scores in 13-16 year olds (Lagrou et al., 1998). Lagrou et al. (2006) found no significant 
differences between GH treated girls with TS and age matched controls, other than the TS group 
reporting more attentional difficulties, fewer delinquent behaviours and perceiving themselves as less 
socially competent.  
Van Pareren et al. (2005) compared psychosocial functioning in girls with TS after GHT had been 
discontinued for six months, to a normal population control group. The results showed self-perception 
and bodily attitude were significantly lower in the TS group, however there were no significant 
differences in behavioural problem or depression scores. Lastly, Siegel, Clopper and Stabler (1998) 
explored the ‘psychological profile’ of GH treated girls with TS and noted significant decreases in 
specific subscales such as social problems, attention and withdrawal over three years.  
With regards to psychosocial functioning, the results are mixed and reveal some paradoxical findings. A 
number of improvements were reported by treated girls in comparison to untreated girls and between 
pre/post GHT trials, for example improvements in self-concept, social relationships, interaction and 
attention (Huismen 1993; Rovet and Holland, 1993; Siegel, Clopper and Stabler, 1998). However, in 
comparison to a normal population group, girls with TS treated with GHT reported significantly lower 
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self-perception scores (Van Pareren et al., 2005) and an RCT found no global differences between treated 
and untreated girls (Rovet et al., 2019).  
The one ‘high quality’ study measuring psychosocial functioning found no global differences between 
treated and untreated girls (Rovet et al., 2019). The two ‘high quality’ studies measuring QoL/HRQoL 
similarly indicate no association with GHT (Butler et al., 2019; Krantz et al., 2019); although participants 
reported an improvement in HRQoL following one year of GHT in the Butler et al. (2019) study, the 
authors suggest the changes are more likely due to factors such as the test re-test phenomenon and 
conclude there was no independent effect of GHT. 
 
Discussion 
This review systematically evaluated the available literature on TS girls treated with GH, to explore 
whether there are any associations with psychological outcomes. To date, the research has mainly focused 
on examining GHT in relation to QoL/HRQoL or psychosocial functioning in girls with TS.  
Initially, the results indicate there could be a small positive association between GHT and both 
QoL/HRQoL and psychosocial functioning in girls with TS. A number of improvements were reported 
following GHT across a variety of outcome measures (Huismen, 1993; Rovet and Holland, 1993; Lagrou 
et al., 1998; Siegel, Clopper and Stabler, 1998; Butler et al., 2019). However, the majority of high quality 
studies found no differences between treated and untreated girls or pre/post GHT (Krantz et al., 2019; 
Rovet et al., 2019). 
There are several factors which could explain the variations within the results. Firstly, differences in 
psychological outcomes could be assumed to reflect differences in treatment success and subsequent 
increased final adult height. A number of studies found positive associations between greater height gain 
or taller adult height and improved QoL (Bannink et al., 2006) or psychosocial functioning (Rovet and 
Holland, 1993; Rovet et al., 2019). However, 6/7 studies examining QoL/HRQoL found no association 
between final adult height and GHT and three non-randomised studies found no correlation between 
height and any individual differences in scores or psychosocial functioning parameters (Lagrou et al., 
1998, 2006; Van Pareren et al., 2005). These results indicate it is unlikely any positive associations 
between QoL/HRQoL and GHT are mediated by an increase in height and further questions the premise 
that reduced QoL in females with TS may be related to short stature (Reis et al., 2018). It is not possible 
to confirm whether height mediates the relationship between GHT and psychosocial functioning in girls 
with TS.  
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Contradictory results highlighted by studies comparing girls with TS to general population samples could 
be indicative of limitations within study designs. Several studies did not compare outcomes pre/post 
treatment; as the researchers did not collect any baseline scores, it is therefore not possible to infer 
whether there were any changes in psychological outcomes in relation to GHT (Van Pareren et al., 2005; 
Bannink et al., 2006; Lagrou et al., 2006; Lašaite, Lašiene and Lašas, 2010). Longitudinal studies found 
no global difference in psychosocial functioning or HRQoL between treated and untreated women 
(Krantz et al., 2019; Rovet et al., 2019) Therefore, it could be argued that any observed positive effects 
may diminish over time.  
Diminished effects could be indicative of an initial bias from both parents and their children to respond 
positively following GHT, given the greater time they have invested, alongside the hope that treatment 
shall result in improved outcomes. Once girls have reached final adult height and on average continue to 
remain shorter than their peers, it could be the case participants’ expectations are more realistic and 
therefore less biased in their reporting. Alternatively, research indicates infertility can negatively impact 
upon psychosocial functioning (Greil, Schmidt and Peterson, 2016) and QoL (Chachamovich et al., 
2010); it may be the case that as girls progress through adulthood, the impact of infertility becomes more 
apparent and/or meaningful.  
Interestingly, in accordance with recent qualitative research in which TS girls viewed themselves as more 
socially competent than parental reports (Wolstencroft, Mandy and Skuse, 2020), two studies found 
parents perceived their daughters social functioning as much lower than girls themselves (Bannink et al., 
2006; Butler et al., 2019). These discrepancies could reflect a social desirability bias, similar to that 
described in young females with ASD (Bauminger and Kasari, 2000). Differences in findings may 
therefore reflect a lack of multi-informant data.  
Moreover, there were several methodological limitations and biases within the included studies. Only two 
studies excluded girls that had received Oestrogen therapy to induce puberty and/or Oxandrolone which is 
an anabolic steroid also used for height gain (Rovet and Holland, 1993; Butler et al., 2019). It is therefore 
not possible to determine whether any changes in psychological outcomes are associated with GHT, one 
of these additional treatments or an interaction between co-interventions. Historically, paediatric 
management of TS focused primarily on height gain, and thereby delayed pubertal development to allow 
more time for growth to improve final height (Turner and Hozjan, 2019). This is no longer considered 
best practice as it fails to recognise the importance of age-appropriate development for psychosocial 
adjustment and general health. Carel et al. (2006) found delayed puberty induction in girls with TS could 
have a long-lasting, negative impact on self-esteem and self-adjustment; any positive or negative effects 
on the psychological outcomes observed may therefore be associated with pubertal development and the 
induction/lack of induction of puberty, rather than GHT.  
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Furthermore, within the RCTs, neither the participants nor the researchers were blinded to which 
treatment group girls had been allocated to i.e. there were no placebo control groups. This is 
understandable given the unethical implications around injecting children daily with a placebo for several 
years (White, 1993). However, a systematic review of trials that randomised patients to blinded and 
nonblinded studies highlighted nonblinded patients exaggerated the effect size by 0.56 SD on average 
(Hróbjartsson et al., 2014).  
Additionally, although the majority of studies used standardised measures, these measures were self-
report questionnaires not specifically designed for TS, and so it is unclear how valid and/or reliable they 
are within this population. Lastly, the studies varied significantly in sample size, with 12/14 failing to 
report whether they had conducted sample size calculations.  
Limitations  
The decision was made to exclude articles in which the effects of Oxandrolone were specifically 
examined in relation to psychological outcomes as this is an adjuvant therapy to GHT. However, future 
research to widen the inclusion criteria to include these studies may highlight additional findings. 
Moreover, one researcher conducted the database searching, screening of articles and data extraction. To 
increase the reliability of the results, the addition of a second researcher at these stages would be of 
benefit. Furthermore, due to time constraints, inter-rater reliability was achieved for 4 of the included 
studies. Two raters independently assessing each of the studies included would have further reduced any 
biases and increased the reliability of the results. While the search strategy was comprehensive and the 
search terms were reviewed by a member of the University library team, literature outside of searched 
databases may exist, in languages other than English.  
Clinical and Research Implications  
Although improvements were reported across several psychological domains following GHT in girls with 
TS, the lack of consistency across findings alongside several methodological limitations and biases found 
within the included studies, limit any conclusions that can be drawn. Moreover, several high-quality 
longitudinal studies indicate no association between GHT and psychological outcomes. QoL/HRQoL 
and/or psychosocial functioning should therefore not be used as a primary measure to determine whether 
girls with TS should receive GHT; it could be argued that height enhancement alone should be considered 
the main rationale for providing GHT to girls with TS.  
It is therefore important clinicians do not over-emphasise the benefits of GHT on psychological outcomes 
and manage both parents and girls’ expectations. Given the expense, considerable commitment required 
by girls and their families, and substantial variation in treatment response, both clinicians and families 
should carefully consider whether to pursue GHT. It should also be noted several studies found 
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alternative variables such as ontological involvement, cardiac involvement, BMI and age at diagnosis 
were negatively associated with QoL/HRQoL and/or psychosocial functioning. The management of TS in 
relation to psychological outcomes should thus be person-centred, tailored to the individual and consider 
how a range of TS associated health problems may impact upon psychological well-being.  
Ideally, future research exploring the association between GHT and psychological outcomes would utilise 
double-blinded trials in which girls with TS are randomly allocated to either GHT or a placebo, including 
both multi-informant and multi-method outcome measures. However, the ethical implications of such a 
trial render this as unfeasible. It could be helpful to conduct further follow-up studies of the Canadian 
RCT to determine whether there are any associations between GHT and psychological outcomes as 
women progress through adulthood. Lastly, whether or not short stature does result in psychological 
disadvantages continues to be a topic of debate within the literature. Earlier studies suggest short stature 
individuals experience poorer quality of life and problems with psychosocial adaptation due to chronic 
psychosocial stress (teasing and stigmatisation) and/or height-related physical limitations (Wheeler et al., 
2004, Voss, 2001). However, a recent review concluded teasing alone is not associated with dysfunction 
and height as an isolated characteristic, does not impair positive psychosocial adaptation (Sandberg and 
Gardner, 2015). A clearer theoretical framework may help determine more sensitive and focussed 
measurement of the impact of increased growth on psychological wellbeing. Although there are a small 
number of outcome measures which assess HRQoL/QoL in children and adolescents (Bullinger et al., 
2013) and adults (Holmes et al., 1995) with SS, these questionnaires have been developed for individuals 
with GH deficiency. Therefore, a TS-specific instrument may beneficial.  
 
Conclusion 
The current literature exploring whether there are any associations between GHT and psychological 
outcomes in girls with TS, primarily investigates QoL/HRQoL or psychosocial functioning. Although the 
results indicate there could be positive associations within a number of psychological outcomes, it is 
unlikely GHT leads to global, long lasting improvements. Several methodological biases such as failing 
to control for co-interventions and lack of participant and researcher blinding were found throughout the 
literature and may explain some of the variability within the results. These limitations are consistent with 
those noted by Gardner et al. (2016) in a systematic review examining the risk of bias in the literature 
around the effects of GHT on psychological outcomes in children with general SS. When managing 
treatment, clinicians should avoid over-emphasising the benefits of GHT and use a person-centred, 
holistic approach to consider how the wide variety of possible TS-related health problems may impact 
upon psychological outcomes in girls with TS.  
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Plain English summary 
Title 
A qualitative study exploring disclosure in girls with Turner Syndrome: their experience of diagnostic 
disclosure and disclosing their condition to others. 
Background 
Historically, clinicians tended not to share a diagnosis of illness with children to protect them from 
distress. However, more recently, doctors have been encouraged to adopt a much more open approach. 
Although there is a lot of research around how to tell a child about illnesses such as HIV or cancer, there 
is far less around how to tell a child about a genetic condition. Turner Syndrome (TS) is a genetic 
condition which affects females, causing difficulties such as short stature and infertility. Preliminary 
research suggested that in the past, some girls with TS had not been told they have the condition 
(Gravholt et al., 2003) or not been told TS affects fertility (Sutton et al., 2006). To date, there has not 
been any research exploring how girls with TS feel disclosing their condition to others, or how TS affects 
families as a unit. Research conducted from the joint perspectives of girls with TS and their parents is 
also limited.  
Aims 
The main aim of this study was to explore the experiences of diagnostic disclosure and disclosure to 
others in adolescent girls with TS and their parents/guardians. A further aim was to examine the impact of 
TS on girls and their family’s lives. 
Method 
This research used a qualitative design. Five girls with TS aged between 12-25 and at least one of their 
parent/guardians were recruited from two local TS clinics in Scotland. Participants completed semi-
structured interviews together and then individually, which were audio recorded and later transcribed. 
Interpretative Phenomenological Analysis (IPA) was used to analyse the results. IPA focuses on the way 
people make sense of their experiences and beliefs, which are interpreted by the researcher. This leads to 
a very in-depth understanding of a particular phenomenon. Interviews were coded and the researcher 
identified themes occurring across the five interviews.  
Results 
Three main themes were identified: Communication and Support, Stigmatisation of TS and Psychological 
Consequences. These main themes included eleven subthemes, which are discussed alongside relevant 
quotes from the participants. 
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Conclusions 
This study adds to the limited research around disclosure in girls with TS, indicating that although 
families feel they are very open discussing TS with each other, both girls and their parents avoid telling 
others about the condition. The results highlight variations in the way TS can affect families, from the 
unique, joint perspectives of girls and their parents. These insights provide recommendations for parents 
and clinicians, and suggest more research is required to explore factors which may help enable girls to 
disclose TS to others.  
References 
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Abstract 
Objectives 
Previous literature exploring diagnostic disclosure in girls with Turner Syndrome (TS) is limited and has 
not yet examined how girls feel about disclosing their condition to others. Moreover, research conducted 
from the joint perspectives of girls and their parents is lacking. The primary aim of this study was to 
explore the experiences of diagnostic disclosure and disclosure to others in adolescent girls with TS and 
their parents/guardians. The secondary aim was to examine the impact of TS on girls and on their 
family’s lives.  
Design 
A qualitative method utilising Interpretative Phenomenological Analysis (IPA) was employed within this 
study.  
Methods 
Five girls with TS and one parent/guardian of each girl completed dyadic and individual semi-structured 
interviews. Interviews were audio recorded and analysed verbatim. Data were analysed in accordance 
with IPA guidelines, with a focus on the dynamic interactions within dyads.  
Results 
Analysis identified three superordinate themes across the ten participants’ accounts: (i) Communication 
and Support, (ii) Stigmatisation of TS and (iii) Psychological Consequences. Eleven related sub-themes 
are described alongside relevant quotations.  
Conclusions 
The present findings provide insight into the lived experience of receiving a diagnosis of TS, highlighting 
a desire from both girls and their parents to conceal TS from others and demonstrating the varying impact 
TS can have within families. These insights provide potential recommendations for both clinicians and 
parents, such as ensuring direct conversations about infertility occur within treatment and facilitating 
open, honest communication. Future research exploring barriers around disclosure to others may enable 
girls and their families to facilitate this conversation.  
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Introduction 
Diagnostic disclosure in children 
Historically, clinicians took a ‘protective approach’ when communicating a diagnosis of an illness or 
condition to children, the rationale being that children should be shielded from distress (Sisk et al., 2016). 
However in recent years, a more open approach has been recommended, taking hope and prognosis 
(Mack et al., 2006), individual differences (e.g., developmental stage; Bluebond-Langner, Belasco and 
DeMesquita Wander, 2010) and family culture (Bluebond-Langner et al., 2007) into consideration.     
Poor communication or insensitive care from health professionals during diagnostic disclosure appears to 
result in negative consequences for both children and their families (Davies, Davis and Sibert, 2003; Stein 
et al., 2019). Research exploring children with a diagnosis of cancer found that poor communication 
between clinicians, parents and children can increase the suffering of patients and their families (Sisk et 
al., 2016). Gaff and Bylund (2010) note that if a diagnosis is withheld it could evolve into a family secret, 
resulting in an environment of distrust and strain affecting family interpersonal relationships.  
Moreover, research exploring adolescents’ views and experiences of disclosing conditions such as autism 
and HIV highlighted teenagers are often reluctant to tell others about their diagnosis, for fear of being 
treated differently or experiencing stigma (Humphrey, Neil and Lewis, 2008; Michaud et al., 2009). 
Metcalfe et al. (2008) found children with genetic conditions rarely discussed the condition or its risks 
with their siblings. Most communication took place between the child and parent(s). In addition, it has 
been recognised that when a child is unwell, the whole family is affected (Stein et al., 2019). Therefore, 
clinicians are encouraged to adopt family-centred models of paediatric care, which include the potential 
impact of the illness on parents/carers (Watts et al., 2014). Prior studies have identified considerable 
variety with regards to the level of impact a child’s chronic condition can have on family functioning and 
quality of life (Barlow and Ellard, 2006).  
While most diagnostic disclosure studies focus on children with intellectual disabilities, HIV or cancer, 
there is less research exploring disclosure in children with genetic conditions. Turner Syndrome (TS) is a 
genetic condition which occurs in between 1:2000 and 1:2500 live born females (Stochholm et al., 2006; 
Apperley et al., 2018) The condition is caused by the complete or partial absence of the second X 
chromosome. TS is characterised by short stature and infertility, alongside a broad range of other 
phenotypical characteristics such as an increased risk of renal and heart defects (Hall and Gilchrist, 1990). 
The age at which girls are diagnosed can therefore vary, from the antenatal period through to adolescence, 
depending on which features are evident (Apperley et al., 2018). 
Diagnostic disclosure in girls with TS 
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Preliminary research suggests that in the past, individuals with TS may not have always been informed of 
their diagnosis or may have had some aspects of the condition withheld from them. Gravholt et al. (2003) 
conducted a questionnaire study to explore the characteristics and risk factors for bone fractures in 
women with TS. Unexpectedly, they discovered 45/322 participants they surveyed were unaware of their 
TS diagnosis. Further qualitative research by Sutton et al. (2005) explored the challenges experienced by 
females with TS across the lifespan; many participants spontaneously reported that some aspect of the TS 
diagnosis had been kept secret from them. Secondary analysis examining the impact of secret-keeping on 
girls and women with TS suggested parents are the most likely individuals to withhold diagnostic 
information from their daughters, particularly around the infertility component (Sutton et al., 2006). A 
recent cross-sectional study indicated age and emotional maturity were key factors in determining when 
parents would choose to discuss infertility with their daughters with TS (King et al., 2016). Being afraid 
of negative emotion and struggling with the balance of educating plus protecting their daughters were two 
of the main barriers which affected parent’s ability to have the conversation.  
To date, most studies have explored the views of parents of a child with TS or adult women with TS. To 
our knowledge, there has been no prior research conducted which focuses on the joint perspectives of 
adolescent girls with TS and their parents. Given that a moderate percentage (26%) of girls receive their 
TS diagnosis within the first year of infancy (Apperley et al., 2018), it is likely their parents or guardians 
will have been involved in the disclosure process, and therefore a joint account may provide a more in-
depth understanding. Moreover, TS is likely to impact individual members of a family as well as families 
as a whole and so joint interviews will provide important insight into any similarities or differences in 
experiences. Analogous research exploring the experiences of parent-child dyads within families affected 
by Huntington’s disease highlights the importance of co-constructed accounts within the process of 
meaning making (the dynamics and interactions between them) (Maxted, Simpson and Weatherhead, 
2014). Advantages of dyadic interviews include the opportunity to bring interaction into the interview 
(Kitzinger, 1995) and expand the coverage of the research topic by participants sharing their point of 
view (Morgan, Eliot, Lowe, & Gorman, 2015). Therefore, this study interviewed girls and parents 
together.   
Conversely, previous research also indicates family members may not talk openly in front of each other to 
an interviewer if they worry about criticising or raising sensitive topics which could hurt another’s 
feelings or damage the relationship (Morris, 2001; Corbin and Morse, 2003). Girls and their 
parents/guardians were subsequently also interviewed separately.  
Overall, prior research exploring the nature of disclosure in girls with TS is limited. The issue of 
diagnostic disclosure was highlighted by chance, and subsequent research aimed to describe the perceived 
effects of secret-keeping on females with TS, rather than explore the nature of disclosure as a process 
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within the family (Sutton et al., 2006). Although King et al. (2016) provides further insight into why 
infertility may be a difficult aspect of TS to discuss for parents, their study is quantitative in nature. 
Qualitative methods may arguably provide a more holistic view, and help to develop a richer 
understanding (Bogdan and Taylor, 1975). Lastly, as far as we are aware, no prior research has been 
conducted to explore how girls with TS feel about disclosing their condition to others, and the extent to 
which TS impacts upon families as a system has not yet been explored.  
Aims  
The primary aim of this study was to explore the nature of disclosure in adolescents with TS, including 
how girls learned they had TS, how they feel/felt disclosing their condition to others and parents’ 
experience of discussing and potentially disclosing aspects of TS to their children. The secondary aim of 
this study was to explore whether TS has had an impact on girls and their family’s lives.  
 
Method 
Design  
A qualitative approach was employed, and Interpretative phenomenological analysis (IPA) was the 
method of analysis. The aim of IPA is to explore in detail the processes through which participants make 
sense of their own experiences, focusing on their own perceptions, understanding and views (Brocki and 
Wearden, 2006). As this study explores patients’ lived experience of having a health condition, which 
naturally plays a significant part in their lives and concerns of those with the condition and their families, 
IPA was decided to be the most appropriate method of analysis. The aim of this study was to develop a 
rich insight into parents’ and girls’ experiences of disclosure and the impact of TS on their lives; one of 
the key benefits of IPA is that it offers an in-depth approach, detailing the processes of meaning making 
about a particular phenomenon. It was felt that IPA would therefore further add to the evidence base, by 
gaining a richer understanding from the participants. This method should not only provide insight into the 
experiences of each parent and child but also the points of divergence and convergence in their 
experiences and the dynamics between them. IPA also represents an accessible approach for a researcher 
without expertise in qualitative methods (Smith, Flowers and Larkin, 2009).  
Participants  
Participants were five girls who had been diagnosed with TS and one of each of their parents/guardians. 
Participants were recruited from two designated TS clinics within NHS Greater Glasgow and Clyde 
between October-December 2019: a children’s clinic and an adult clinic. The participant inclusion and 
exclusion criteria are outlined below:  
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Participants with TS  
Inclusion criteria: 
• Aged between 12-25 years old.  
• Received diagnosis of Turner Syndrome. 
• Have at least one parent/guardian who also wishes to take part. 
Exclusion criteria: 
• Participants with a significant learning disability (LD). (Participants who do not or did not attend 
mainstream school were not included). 
• Participants that do not speak English.  
Parents/guardians  
Inclusion criteria: 
• Be the parent/guardian to a girl aged between 12-25 years old diagnosed with TS. 
Exclusion criteria: 
• Participants that do not speak English.  
 
Sample size and data saturation  
Due to the depth and detail of the analysis to understand a particular phenomenon, a small purposively 
selected sample was deemed appropriate (Smith, Flowers and Larkin, 2009). We therefore expected to 
reach saturation of themes by interviewing 6-8 girls and at least one of their parents/guardians. Similar 
qualitative studies interviewing dyads recruited around the same number of participants (Akeson, Worth 
and Sheikh, 2007; Maxted, Simpson and Weatherhead, 2014). However, Smith, Flowers and Larkin 
(2009) suggest between 3-6 participants can be a reasonable sample size for student studies using IPA.  
Ethics  
Ethical approval was obtained through the West of Scotland Ethics Committee (REC) (Appendix 2.1) 
(ref: 19/WS/0132) and the NHS Greater Glasgow and Clyde Research and Development Department (ref: 
GN19MG312).  
With permission from participants, all interviews were recorded using a portable audio recording device 
and then uploaded to a secure server. The audio files were deleted from the device and each participant 
was assigned a unique code and pseudonym. Interviews were transcribed using only the identifier code 
and any identifiable information (e.g. hometown) was removed.  
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Recruitment and Procedure  
The lead clinicians from the TS clinics invited the girls and their parents/guardians to take part via post. 
Participant information sheets (PIS)(Appendix 2.2) were posted alongside the invitations. Girls with TS 
aged over 18 years old, who may not live with their parents, were also sent the parent/guardian PIS sheet, 
and asked to distribute this to their parents/guardians.  
There were two methods in which participants could indicate consent. Firstly, they could contact a 
member of the research team prior to their appointment if they wished to take part. Alternatively, the lead 
clinicians asked all potential participants if they would like to take part when they attended the clinic. If 
they indicated they would like to take part, the Principle Investigator (PI) contacted them to provide any 
further information required and arrange the interview. The PI also attended both clinics to provide 
further information about the study and answer any questions from potential participants.  
Prior to each interview, the PIS was supplied for the participants’ review and any questions answered. 
Written consent was then obtained (Appendix 2.3). One interviewer conducted semi-structured, face-to-
face in person interviews, lasting between 53-92 minutes. Girls and their parents/guardians were initially 
interviewed together using a dyadic interview approach. Both parties were then interviewed individually 
unless they chose to decline. All interviews were transcribed verbatim.  
Interview 
The interview schedule was developed by the Trainee Clinical Psychology, in consultation with the lead 
clinician who facilitated the children’s TS clinic and another researcher who is a Clinical Psychologist 
working within a Paediatric Clinical Psychology service (Appendix 2.4). The aim of the schedule was to 
facilitate a comfortable interaction with participants to help them feel at ease, thereby enabling them to 
provide an in-depth account of their experiences (Smith, Flowers and Larkin, 2009). Open-ended, 
expansive questions were prepared in accordance with the sequence described by Smith, Flowers and 
Larkin (2009); the range of topic areas and how to sequence these were considered alongside how to 
phrase each question and related prompts, before further discussion with members of the research team 
and re-drafting as appropriate. To explore participants experience of diagnostic disclosure, the girls were 
asked "Can you tell me a bit about how you found out you had Turner Syndrome?" and their 
parents/guardians were asked "Can you tell me how you found telling (participant) about the aspects of 
their condition?". To investigate the experience of disclosure to others, girls were asked "How do you feel 
talking about your condition to others?".  
Data analysis 
Data were analysed using IPA in accordance with the steps and procedures outlined by Smith, Flowers 
and Larkin (2009), before conducting an overarching analysis within each dyad, focusing on the 
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interactions between participants (Morgan et al., 2015; Van Parys et al., 2017). To ensure concepts and 
themes were constructed from participants individual perspectives, the transcripts were initially analysed 
individually. The transcripts were then read and re-read, whilst taking initial notes. Line by line coding 
was conducted to increase methodological rigour, the initial codes representing different levels of 
interpretation: descriptive, linguistic and conceptual. Emergent themes were developed, before moving on 
to the next member of the dyad. Emergent themes were organised into three categories; ‘Individual with 
TS’, ‘Parent’ and ‘Both’ to reflect whether the interpretations were experienced by individual members of 
the dyad or both members. Each dyad’s emergent themes were finally integrated and analysed across all 
family units to produce overarching superordinate themes (Van Parys et al., 2017).  
We acknowledge the dyadic approach utilised is not typical of IPA, in that researchers would usually seek 
out a single and reasonably homogenous sample of participants. However, a number of studies have used 
IPA to explore complex, systemic experiences from multiple perspectives (Burton, Shaw and Gibson, 
2015), and a recent article outlines a series of multiple perspective designs and analytic procedures using 
IPA, which can be adapted and used across diverse populations and settings (Larkin, Shaw and Flowers, 
2019). The authors propose dyadic designs in particular are able to maintain a strong idiographic focus, 
because couples or family members provide us with a coherent and familiar unit of analysis. 
Reflexivity  
Reflexivity has been established as one of the methods researchers use to ensure rigor, trustworthiness 
and quality within qualitative research (Dodgson, 2019). The PI therefore maintained reflective notes 
throughout the data collection, transcription and analysis, with the aim of continually refining the 
thematic process. The PI was able to revise codes and themes to reflect the experiences and interactions 
between girls and their parents, until they were an accurate interpretation of the data as a whole. The PI is 
a female, trainee clinical psychologist and prior to contacting participants that had indicated they would 
like to take part, she had no relationship with them. She had no prior clinical or research experience of 
working with females with TS. Her background in clinical psychology training facilitated the interviews 
and data analysis, given her experience conducting assessments, building relationships with clients, and 
interpreting and analysing language within sessions.  
Two of the five transcripts were separately coded by an independent investigator (trainee clinical 
psychologist) to reduce researcher bias and improve the quality of the study. We hope the inclusion of an 
additional investigator's viewpoint improves the credibility of the results, through the process of 
triangulation; the codes were compared and discussed to reach an agreement, arguably increasing the 
scope and deepening the understanding of the interpretation (Tracey, 2010).The PI acknowledges that 
prior to conducting the interviews she expected girls to report negative experiences regarding diagnostic 
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disclosure. The PI also recognises the influence her own life experiences and position as a clinical 
psychologist may have had on her interpretation of the data.              
 
Results 
Five girls and five parents/guardians completed semi-structured interviews with the PI. Each parent-child 
dyad was initially interviewed together and then separately, in accordance with the protocol. None of the 
participants declined the individual interview. Relevant participant characteristics are outlined below in 
Table 1. Their names are pseudonyms. 
Table 1. Characteristics of participants 
Participant Age 
(years) 
Age at diagnosis 
(years) 
Age at diagnostic disclosure 
(years) 
Parent 
Sarah 16 Birth  There was no one defining 
moment of diagnostic 
disclosure; Jack estimated Sarah 
was around 5 as this was when 
she began receiving growth 
hormone injections. 
Jack 
Mary 17 13 13 Jim 
June 21 Birth  Jane estimated around 4 or 5. Jane 
Lisa 17 8 8 Amy 
Erin 14 Birth  There was no one defining 
moment disclosure; neither Erin 
nor Sue could recall a specific 
age. 
Sue 
 
Three Superordinate and eleven related subthemes were identified; the results are presented in Table 2 
below. Each superordinate theme and associated sub-theme are outlined in detail, alongside relevant 
quotations to illustrate participants' lived experience. As stated, the data were analysed to capture both 
individual and shared experiences. Therefore, each sub-theme indicates whether it represents the 
experiences of girls, parents or both members of the dyad. The results have been presented in an 
integrated manner, in line with each superordinate theme as this was felt to be the most coherent, 
systematic narrative.  
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Table 2. Superordinate themes and related subthemes  
Theme Subtheme Participant (Individual 
with TS/Parent/Both)* 
Communication and support Disclosure as a process Both  
The process of acceptance  Both  
Open communication within 
support systems 
Both 
Stigmatisation of TS Avoid diagnostic disclosure Both  
Infertility; the elephant in the 
room  
Both  
I am not disabled  
 
Individual with TS 
Separation between TS and the 
self 
Both 
Psychological consequences Avoidant coping strategies  Both  
I’m not good enough  Both  
Anxiety and Uncertainty  Both 
Self-fulfilling prophecy  Parent  
 
*Subthemes representing the experiences of individuals with TS, their parents or both members of the 
dyad.  
COMMUNICATION AND SUPPORT 
Disclosure as a process 
Whilst the two girls diagnosed with TS aged 8 and 13 were informed by a health professional (HP), the 
parents of girls who were diagnosed at birth (3/5) reported being significantly involved in disclosing the 
condition to their daughter, and described disclosure as a gradual process over time: 
“It was done subtly and naturally all throughout, all throughout her life.” (Sue) 
Progressively disclosing TS appeared to be a conscious decision, aimed at minimising potential distress, 
and increasing the likelihood of successful adaptation to the condition. Developmental age and stage were 
factored into the decision-making process, in relation to when to disclose certain aspects of TS: 
“Some parts I suppose we told her at that age and some parts maybe a bit later. I mean with your 
children, you know infertility, you’re not going to tell an eight-year-old everything” (Jack) 
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4 of the 5 girls could not recall many specific memories around diagnostic disclosure and tended to seek 
the information from their parents, who in turn, were able to provide much more detailed accounts. The 
lack of detail could signify that as children, the initial disclosure had minimal impact on their self-
concept, whereas for parents, recalling the disclosure appeared to be a much more emotive topic, 
indicating greater significance. The girls appeared to develop an understanding and attach subsequent 
meaning to their condition gradually over time:  
“[infertility] I think when I was younger it never really mattered, it never really….came to me what it 
was, em, until I kind of started high school and I realised this is kind of quite a big thing. This could have 
a big impact on my life.” (Lisa) 
The process of acceptance  
Both the girls and their parents similarly describe coming to terms with the diagnosis as a gradual process 
over time: 
“I’m slowly coming to terms with it.” (Sarah) 
“You need time to process it yourself…definitely over the years I have gotten into the swing of things.” 
(Mary) 
The process of acceptance appeared to be endless, continually challenged by changes in the manifestation 
of TS, alongside shifts in what the condition means. One parent spoke about the role that the acquisition 
of knowledge played in accepting her daughter’s diagnosis, which could stem from a reduction in 
uncertainty: 
“And then the more you learn about it the more you think, oh, oh right, oh I can deal with that.” (Jane) 
Lisa and Mary similarly discuss the way in which gathering information helped them understand and 
accept their diagnosis, which was interpreted as a method of feeling more in control. Lisa notes how the 
involvement of siblings in care can aid acceptance, possibly indicating a transition from perceiving illness 
as an individual experience to experiencing illness as a family: 
“I think another thing that’s really helped me in terms of like advice and the advice I’ve been given is 
having [sister] there at the appointments. And she knows so much about it…and like, so like I know I can 
go to her as well and I know that like…I can come to my mum and because they’re just as knowledgeable 
about it as me whose living it.” (Lisa) 
Open communication within support systems 
A systemic culture of openness within families was described by both girls and their parents, suggesting 
childhood illness may, at times, bring families closer together: 
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“I can talk about anything with them, with my turner’s syndrome. My family is quite a close family and 
we all talk.” (Sarah) 
“We can have –“ “Yeah dead kind of frank, honest conversations” “True, me and my mum are dead 
open with each other.” (June and Jane) 
Both girls and their parents reflected on their experiences with HP’s and 4 out of 5 reported an overall 
positive experience of diagnostic disclosure and subsequent management TS. Both members of the dyad 
cited openness and honesty as factors which facilitated a positive experience, signifying the importance of 
trust within the patient-clinician relationship: 
“[consultants] They’ve never sugar coated anything, em, they’ve always explained em eh like...if…like 
everything that was going on, like if my height wasn’t going so well or if the injection needed upped or 
the tablets or if there was something else they wanted to try, the blood tests or everything like that they’ve 
been really open and as my mum said from the get go, em, people have been open and honest.” (Lisa) 
“[nurses name] was fabulous. She was just a very down to earth, caring and quite direct. There was 
never any kind of like oh shhh shhh or anything, she would have been there having conversations with 
June and stuff. Direct conversations.” (Jane) 
STIGMATISATION OF TS 
Avoid diagnostic disclosure 
Conversely, despite all participants reporting open communication within their immediate families and 
generally with HP’s, both parents and girls described a desire to conceal their diagnosis from others. Girls 
appeared to be particularly avoidant in discussing their diagnosis with their peers, highlighting possible 
feelings of shame: 
“if the situation arises and they need to know, I’ll let them know. But otherwise I do kind of keep it to 
myself.” (June) 
The main barrier to diagnostic disclosure for girls was a fear of being treated or perceived differently, 
suggesting the girls had formed outward identities which could, in some sense, be tarnished by the 
disclosure of TS. A quote from June has been used to best demonstrate below: 
“I’d be worried if once I’d let them know…they’d….they’d treat me in a different way, or something like 
that eh, [becomes tearful], I don’t want people’s perceptions of me to be….coloured by this.” (June)  
It's possible girls are modelling their parents’ behaviours; most parents (3/5) subtly encouraged their 
daughter to hide their diagnosis from others and/or avoided disclosing to others out with the immediate 
family: 
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“All turner girls are different but if people are looking at you and just thinking oh you’re small or as Lisa 
says you wear hearing aids or you wear glasses or whatever then just let them accept that, don’t, don’t 
give too much information I think to other people unless you know they specifically ask.” (Amy) 
“I mean, my dad, Erin’s granddad doesnae know. We, we, we didn’t, we haven’t, we’ve shared it with 
just us.” (Sue) 
Infertility; the elephant in the room  
Infertility was highlighted as a particularly difficult aspect of TS to disclose or discuss by both members 
of the dyad, possibly due to infertility being perceived as a more intimate, personal topic, combined with 
perceived stigma:  
“[infertility] Everything else just kind of…leads into like an explanation or something that can be 
explained but then…I don’t really want to talk about that and then….because that feels more personal to 
me than kind of, the height or the hearing. That kind of feels like…my, my thing almost like that’s 
something that I’m going to need to deal with and like, find ways around so, I would struggle talking 
about that a wee bit more.” (Lisa) 
“I still feel uncomfortable….em…talking about things like, like periods and having babies.” (Jack) 
Infertility was often cited much later during the interviews, after height or other TS-specific difficulties, 
which could be indicative of subtle avoidance. Surprisingly, three dyads spontaneously reported HP’s 
might also avoid discussing infertility with girls with TS and their families. Although infertility was never 
kept a secret, the topic was never thoroughly discussed which could similarly reflect underlying 
stigmatised beliefs: 
“It was alluded to in the first appointment.” (Jim) 
“Nobody’s actually ever sat down and had a conversation about it.” (Amy) 
I am not disabled:  
All girls described a fear of being perceived as disabled by others due to TS. Mary discussed this in 
relation to the minimal impact she feels the diagnosis has had on her life overall: 
“it’s not something that you can catch, it’s not contagious. Um…yeah I’ve lived with it for eh…my whole 
life and it never…impacted anything, I was never, you know, unable to do stuff.” (Mary) 
For Lisa and June, the belief that others may perceive them as disabled led them to overcompensate and 
strive to ‘prove’ to others they are able: 
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“I just kind of wanted to prove that I can….that I’m good at maths and I can do this and I can do that, all 
the things that I’m not supposed to be able to do.” (Lisa) 
“because….I wanted to be…the same as everybody else. And to be treated fairly, a level playing field, 
like I can do it….. because…I just practice and study, practice and practice”. (June) 
The worry that others may perceive TS as a disability acted as a barrier for Erin to disclose her diagnosis 
to others: 
“[others] thinking I can’t do things, because I’ve got turners syndrome when that’s not really the case.” 
(Erin) 
Separation between TS and the self: 
Both girls and their parents/guardians reported a strong feeling that TS did not define them as an 
individual, which could be understood as a fight against the diagnosis, or alternatively reflect the minimal 
impact of TS on the girls identity: 
“Feel comfortable knowing that it’s just a part of you, it’s not kind of all of you, it’s just a small, pardon 
the pun [all laugh] but, eh, it’s just a wee bit of you, it’s not….all of you.” (Lisa) 
Sarah relates this to the universality of being a human being: 
“like I have turners syndrome but I’m just like….I’m just like them…in that I am a human.” (Sarah) 
All parents described viewing their daughter as ‘more than a syndrome’, and during the dyadic interviews 
this was interpreted as a way of providing reassurance and normalising TS. Jane’s quote below best 
demonstrates this: 
“they’re not a turner syndrome, they’re a girl who happens to have turner syndrome. They’re a girl not a 
syndrome, they’re just a girl. Just don’t give them a, a something to make them feel they’re odd or….you 
know.” (Jane) 
In conjunction, both girls and their parents described a sense of separation between the self and TS, 
possibly to externalise the condition: 
“I don’t know when it stops being me and kind of more about the condition…so I think with that like, it’s 
trying to disassociate it, like people that I meet from being the condition.” (Lisa) 
“This is not Sarah; this is the Turner Syndrome.” (Jack) 
Alongside interpreting certain behaviours or traits as directly related to TS, some parents also described 
having difficulty differentiating or separating what was TS and what was their daughter’s natural 
temperament: 
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“We don’t, you know, is it turner syndrome? Is this how she would be naturally anyway other than being 
a bit tall, well nobody can answer that question because you wouldn’t know.” (Sue) 
Interestingly, one parent reflected on the image that is portrayed of girls with TS e.g. on the internet. She 
talks about the change in society’s perception of individuals with Down Syndrome and states she feels 
there needs to be a similar shift in the way others perceive TS. This could be interpreted as stepping away 
from a ‘medical model’ of illness towards an individual difference model of acceptance within society:  
“So if you google that you think oh my god is that what’s going to happen to my child? I mean what was 
obviously, that was how it was back then, whereas I just think it could be….yeah overhauled and 
modernised and….a fresher look because there’s probably loads of girls that look like Erin you know… I 
just think…a wee overhaul and let’s not hang on to it…like a badge.” (Sue) 
PSYCHOLOGICAL CONSEQUENCES  
Avoidant coping strategies  
A variety of individual coping strategies were discussed throughout the interviews, however using 
avoidance to cope with TS was a common subtheme across both the girls and parents’ experiences. 4 out 
of the 5 dyads described feeling ‘lucky’; either because they had developed few TS-related physical 
health difficulties or generally believing TS had not significantly impacted on everyday life:  
“I think I’m lucky that I’ve no had any of the major health complications, you know, kidney problems or 
heart problems, all that stuff.” (June) 
“We feel very very lucky it's affected her so little.” (Jim) 
Perceiving themselves as ‘lucky’ appeared to reflect an underlying hierarchy of illness e.g. I have ‘mild’ 
TS in comparison to others, which could be a strategy to distance themselves and avoid feeling like they 
belonged to a TS group. 4 out of the 5 dyads tended to minimise any difficulties: 
“It’s not a big deal, it’s just em…yeah something I’ve lived with my entire life and knowing hasn’t really 
changed that much, so yeah.” (Mary) 
“Lisa has been very fortunate with it, it was a tiny tiny mosaic on you know once of her chromosomes, it 
wasn’t as if it was like really bad.” (Amy) 
June describes a lack of romantic relationships and initially expresses worry that a potential partner may 
reject her because of her TS. However, she appears to then immediately downplay this by stating: 
“like I said, maybe a wee bit bothered but not overly bothered. Because….if I meet someone, I meet 
someone, all good. If I don’t, I don’t. It doesn’t really matter.” (June) 
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Sue describes deliberately concealing her daughter’s diagnosis from her teachers, to wait and see if they 
notice she has TS. Her teachers did not report any concerns which Sue appears to interpret as ‘if you can’t 
see it, it doesn’t exist’: 
“as I say, I put that to the test to the school, for to them to tell me, you tell me there’s something wrong, 
and that’s again why I didn’t tell my mum and dad at the time, and now just my dad obviously, em. You 
tell me, that’s what I was always waiting on, you tell me. And nobody’s ever told me. So.” (Sue) 
Jane similarly seemed to minimise June’s difficulties during the dyadic interview, however when 
interviewed alone she wonders whether her daughter uses avoidance to protect her: 
“Aye she appears to be content but June will…June will tell you what she thinks you want to hear a wee 
bit. And she’ll say that everything’s fine, she’ll say that’s fine, but she’ll no want me to worry, she might 
be doing it to protect me.” (Jane) 
It is possible both girls and their parents minimise any difficulties to protect the other from distress, 
resulting in a cycle of avoidance.  
I’m not good enough 
Several psychological consequences were described in relation to TS. Four dyads reported TS has had a 
negative impact on the girl’s confidence and self-esteem: 
“Maybe I would have slightly more confidence. Some days I feel self-conscious and just generally….a bit 
rubbish about having turners syndrome.” (Sarah) 
“Sarah’s very insecure. She lacks confidence.” (Jack) 
Low confidence and/or low self-esteem appeared to be exacerbated by the tendency to compare oneself to 
others: 
“I think I would have had a slightly different outlook on like...the way I've grown up and stuff and the 
comparison that I make of myself to others.” (Sarah) 
“She compares herself to other folk, like I should be doing this or be the same as him or her or you know 
I should be at that level.” (Jane) 
Jack similarly agreed and noted how although comparing yourself to your peers may be typical of 
adolescents, feeling different from your peers due to TS may intensify negative comparisons:  
“and how she feels, the difference between her and her peers, I can see how much more serious that 
would be than with another child who didn't have TS.” (Jack) 
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Several parents (3/5) describe their daughter developing perfectionistic traits, perhaps to compensate for 
negative self-beliefs around not being good enough: 
“June’s dead cautious and likes to do everything right, doesn’t like making mistakes and stuff.” (Jane) 
Anxiety and Uncertainty  
Several girls (Mary, June and Lisa) spoke about experiencing anxiety and engaging in unhelpful thinking 
patterns such as rumination, in relation to TS and the associated health difficulties and generally across 
day to day life: 
“Every time I went to one [appointment] before, especially endocrine, I just got myself into a big panic 
and that and…I just, it wasn’t a nice feeling.” (Lisa) 
Their anxiety was observed and confirmed by their parents: 
“I used to feel sorry for the wee soul because she used to get quite, quite upset going to clinics. She 
thought something you know bad was going to happen to her so you know, something sore or something, 
and eh, we would have this talk in the car coming on the day getting ready to go, because I used to no tell 
her like, until that day because I didn’t want to worry her, because she worries, she’s stressy.” (Jane) 
TS appeared to generate a great deal of uncertainty for families. The variety in clinical manifestations, the 
unpredictable nature of how the condition develops over time and uncertainty for the future lead to 
difficulties for both girls and their parents:  
“It’s kind of this…unknown kind of thing and nobody was kind of sure what was going to happen with it 
or what sort of things I would have with it.” (Lisa) 
“Again, it was the uncertainty of ‘there might be’ sort of thing, there might be a problem.” (Jim) 
Worries about their daughters' future were particularly evident in parents’ experiences. These concerns 
became more apparent during the parent’s individual interviews, further emphasising the desire to 
minimise difficulties or worries in front of their daughter, to shield them from distress:  
“What we do think about is obviously will it…affect her more, in later life?” (Jim) 
Self-fulfilling prophecy 
As well as making comparisons to others, three parents (Jane, Amy and Sue) talked about the idea of a 
‘self-fulfilling prophecy’ whereby their daughters have been informed girls with TS can have difficulties 
e.g. with math or co-ordination and these beliefs manifest in real-time problems. The quote below from 
Amy clearly illustrates this: 
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“I think the problem she did have at the beginning when Dr Smith said girls can have problems obviously 
with maths, with em, coordination, differences like that, pointed out she could have but I think she took it 
in her head that this is something that she is going to have problems with.” (Amy) 
Experiencing TS-related difficulties may further serve to maintain beliefs around not being good enough.  
 
 
Discussion 
The current study investigated the experience of having TS, specifically focusing on the nature of 
disclosure and the impact of the condition on girls and their families. It explored these experiences from 
the perspective of both adolescent girls and one of their parents/guardians. The analysis revealed three 
key themes; the findings are discussed below in relation to the current literature, considered in light of 
limitations as well as implications for clinical practice and future research.  
Communication and Support 
Consistent with previous qualitative research exploring disclosure in children with genetic conditions 
(Gallo, Angst and Knafl, 2009), parents described disclosing TS to their children as a gradual process, 
dependent on developmental age and stage. The present findings are consistent with cross-sectional 
research indicating in addition to emotional maturity, age acted as a key factor which influenced when 
parents would choose to discuss infertility with their daughters with TS (King et al., 2016).  
Conducting joint interviews appeared to be particularly important in developing an accurate, 
comprehensive narrative around diagnostic disclosure and revealed differences in the emotional impact of 
receiving the initial diagnosis. The girls recalled few memories around diagnostic disclosure, frequently 
turning to their parents for detail, and in turn parents were able to expand upon the topic, often reporting 
significant distress and feelings of shock following diagnostic disclosure.  
Gradual disclosure appeared to be used as a strategy to facilitate acceptance of the diagnosis, alongside 
the acquisition of knowledge and a shift towards experiencing illness as a family rather than an 
individual. Overall, 3 out of the 5 dyads expressed the belief that TS did not currently significantly impact 
upon their day to day life. Due to the wide variability in clinical manifestations, it could be the case that 
these girls suffer from fewer TS-related health difficulties and families have therefore adapted well to 
living with a health condition. The culture of openness and honesty described within family and wider 
support systems may have also facilitated successful adjustment to TS; Robinson (2017) notes having an 
open support system and being able to ‘share the experience’ helps both individuals and their families 
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successfully manage chronic illness. There did not appear to be a finite end to the process of acceptance, 
which may reflect the way in which TS can continually change and develop across the lifespan. 
In contrast to previous research (Sutton et al., 2006), none of the girls reported perceived secret-keeping 
in relation to their diagnosis from either their parents or HP’s; a culture of openness and closeness 
between parents and children was reported by all five dyads. Moreover, 4 out of the 5 dyads reported a 
positive disclosure experience, citing honesty and openness as key contributing characteristics. These 
findings may reflect positive changes in the way clinicians and parents have approached the disclosure of 
TS over the last two decades. The results are consistent with recent guidance produced for the successful 
lifelong management of females with TS, which emphasises the importance of open and truthful 
communication from HP’s (Turner and Hozjan, 2019).  
Stigmatisation of TS 
Conversely, both girls and their parents expressed a desire to conceal the TS diagnosis from others, which 
could be indicative of perceived or experienced stigma in relation to TS. In conjunction with qualitative 
research exploring the experiences of adolescents with visible and invisible chronic illness (Kaushansky 
et al., 2017), girls discussed the particular challenges around disclosure to peers. Kaushansky et al. (2017) 
identified perceived fear of rejection, pity and fear of being perceived as vulnerable or different as key 
barriers to disclosure; these results are strikingly similar to barriers to disclosure cited in the current 
study, consistent with the sub-theme ‘I am not disabled’.  
A distinction can be made between perceived or anticipated stigma and experienced or ‘felt’ stigma. 
Anticipated stigma refers to the degree to which individuals expect others will discriminate or reject them 
if they disclose a ‘stigmatised identity’, such as an illness or disability (Quinn and Chaudoir, 2009). This 
may be particularly relevant for individuals whose condition or illness is invisible, as unlike those with a 
visible illness they may not know how someone will react when they disclose. Although girls with TS are 
small in stature, many of the girls and parents referred to height as being the ‘only’ visible characteristic 
of TS and therefore, for some, TS could be defined as an invisible illness. It could be the case that 
perceived or anticipated stigma is more prevalent in girls with TS rather than actual experienced stigma; 
only one of the dyads reported experiencing discrimination or teasing as a result of having TS.  
Consistent with previous literature (Sutton et al., 2006), infertility was described as being particularly 
difficult to discuss/disclose. A subtle avoidance of infertility was also evident during the interviews. 
Surprisingly, 3 of the 5 dyads reported HP’s showed signs of avoidance in relation to infertility. HP’s 
hesitation around discussing infertility could reflect underlying beliefs that infertility is shameful or 
taboo, thereby acting as a predisposing factor for families to form stigmatised beliefs. These findings are 
consistent with literature describing the social stigma (Ergin et al., 2018) and ‘secret stigma’ (Whiteford 
and Gonzalez, 1995) accompanying infertility. 
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A distinct sub-theme representing the experience of girls with TS demonstrated that they did not want to 
be perceived as having a disability, which could be linked to the perceived negative connotations around 
disability. Sociological research around disability stigma suggests historically, disability has been seen as 
a form of involuntary social deviance, signified by physical differences, which generates negative 
responses from others (Grue, 2016). It could be the case that although the girls do not perceive 
themselves as being disabled, they worry others will attach this label, should they disclose TS. The 
determination expressed by a few of the girls to ‘prove’ they are able or intelligent could also be 
interpreted as a desire for normalcy; previous research has suggested young people diagnosed with a 
chronic illness can feel different from their peers and therefore strive to present themselves as ‘normal’ to 
protect or reinforce a nondifferent identity (Benson et al., 2015).  
The stigmatisation of TS may coincide with both the girls' and parents’ tendency to view the diagnosis as 
part of their self-identity but in no way the whole of oneself. Perceptions of stigma due to illness can 
significantly affect individuals identity and sense of self (Kleinman, 1988). The girls and their parents 
could be, in some sense, compartmentalising or externalising the diagnosis, as a way of protecting the 
girl’s nondifference identity. The extent to which individuals felt TS was separate from their self-concept 
seemed to vary, reflecting differences in the perceived impact of the condition. Therefore, it could also be 
the case that girls who are not significantly impacted, view TS as less meaningful and less integral to their 
sense of self.  
Psychological consequences  
Although 3 out of the 5 families reported little impact of TS on their lives, the majority of dyads seemed 
to minimise TS-related difficulties, often through the perception they were ‘lucky’ in comparison to other 
girls with TS. Minimising their difficulties was initially interpreted as an avoidant method of coping. 
Avoidance has similarly been highlighted as a common coping strategy used by adolescents with a range 
of health conditions such as diabetes (Iturralde, Weissberg-Benchell and Hood, 2017), asthma and celiac 
disease (Oppenheimer et al., 2018). Avoidant coping may relate to the previously described normalcy 
theory; minimising difficulties alongside concealment of the diagnosis could facilitate the 
compartmentalisation of TS as separate from the self, in the pursuit to feel ‘normal’. However, the 
researcher recognises that the 'Avoidant coping strategies' subtheme could reflect an underlying bias, 
stemming from her own life experiences and experience as a trainee clinical psychologist. She 
acknowledges she has an awareness of the potential impact of physical health difficulties on well-being 
and therefore viewed participants as having existing underlying difficulties which were minimised during 
the interviews. These beliefs could reflect a 'medical model' of disability, and she noted she felt hesitant 
to include this subtheme, for fear of offending the participants. An alternative interpretation could suggest 
that both girls and their parents genuinely do not perceive TS significantly impacts their daily lives, either 
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due to having few TS-related health difficulties or having formed adaptive, 'strength-based' cultures 
within their family units.   
Consistent with previous research (Liedmeier et al., 2020), several girls reported anxiety and/or perceived 
a negative impact of TS on their confidence and self-esteem. Interviewing dyads jointly helped to provide 
a deeper level of understanding around this topic; when the girls described not feeling good enough, their 
parents often expanded the interpretation. For example, parents subsequently described their daughters 
developing perfectionistic traits to compensate for negative self-beliefs, alongside the idea of a self-
fulfilling prophecy. If the girls have a belief or expectation they will struggle or fail e.g. at math and these 
beliefs manifest in real problems, this could further compound the idea they are not good enough.   
In line with prior research around uncertainty due to illness (Mishel, 1988; Brown and de Graaf, 2013), 
the wide spectrum in disease severity and unpredictable nature of how TS develops over time appeared to 
generate a great deal of uncertainty for families. Uncertainty about their daughter’s future and general 
concerns around TS became particularly apparent during parent’s individual interviews. The inclusion of 
both individual and joint interviews highlighted a circular pattern of protection between dyads; however, 
this was particularly evident in parents. It could be the case parents felt if they expressed concerns about 
the future this would exacerbate their daughter’s anxiety or fear of being different to others, and therefore 
they especially minimise difficulties in their daughters presence as a method of protection.  
Limitations 
We recognise this study included a wide age range of participants with TS; TS is a rare condition and 
therefore the sample population in which to recruit from was relatively small. Although this study aimed 
to recruit a homogeneous sample, the age at which girls had been diagnosed with TS varied amongst 
participants, which may have impacted upon their accounts. Differences in the experience of disclosure 
were highlighted between girls diagnosed at birth and girls diagnosed in later childhood/adolescence, and 
this may also impact upon other areas of life. Reimann et al. (2018) found receiving a TS diagnosis over 
the age of 13 could contribute to adverse outcomes relating to lack of perceived competence and 
depression.  
Moreover, the families who volunteered to take part did so in the knowledge they would be asked to 
discuss the topic of disclosure together. The sample may therefore be biased towards families who have 
an existing culture of openness around the topic of disclosure. Individuals with poor or no relationships 
with their parents may also have been reluctant to take part. Lastly, we excluded participants with a 
significant LD; it is possible individuals with an LD and their parents may feel TS has had a much greater 
impact on their day to day lives.  
Implications for clinical practice  
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The results indicate HP’s should ensure they initiate explicit discussions around infertility with girls and 
their parents. HP’s may wish to reflect upon their own beliefs around fertility and their role in relieving 
patients of perceived stigma in relation to infertility; some researchers suggest clinicians have a duty to 
protect and counteract harm done to patients due to infertility stigma (Cook and Dickens, 2014). A 
question arises around whose responsibility it is to inform girls of the fertility difficulties associated with 
TS, be that clinicians or parents. It could be helpful for clinicians to raise this topic with parents, to agree 
upon how to navigate the disclosure of infertility and encourage parents to utilise a ‘drip feed’ approach. 
A similarly gradual process of disclosing infertility to girls may facilitate successful adaptation. 
Understanding the positive impact of open, honest communication within family systems and wider 
support systems highlights the importance of establishing this approach from initial diagnosis, to build an 
effective foundation for continued care and management of TS. Girls and their parents might minimise 
TS-related difficulties, which could arguably act as a barrier to help-seeking behaviours; if families wish 
to portray a ‘normal’ identity they may be less likely to engage with services or seek support. Consistent 
with current guidelines, this study recommends clinicians continually assess and monitor mood and 
psychosocial functioning and encourage girls and their parents to seek and utilise additional supports 
when necessary.  
This study may also have wider implications around how society view’s TS and difference, suggesting 
that stepping away from a ‘medical model’ to a ‘strength-based model’ or model of individual differences 
could benefit girls and their families. Perhaps viewing TS as a neutral difference rather than a negative 
abnormality which needs to be ‘fixed’, would also facilitate successful adjustment and minimise the 
impact of TS, as observed in the current study.   
Implications for future research 
When considering disclosure in future research, comparisons between girls diagnosed at birth and girls 
diagnosed in later childhood/adolescence may be helpful, as this likely impacts upon girls and their 
family’s experiences. Further research around how to enable disclosure of TS to others may help to 
inform future care guidelines; the inclusion of advice around how to disclose TS to others could thus 
become a standard element of TS management. Moreover, future research exploring clinicians' perceived 
barriers to discussing infertility may provide further insights into infertility stigma and provide 
recommendations around how clinicians can manage this.  
This study highlights acceptance of TS as a process and therefore additional research to specifically 
examine this process could provide insight into factors which facilitate or hinder successful acceptance 
and adaptation as a family. Considering the differences in how TS can impact upon individuals and 
families, further research exploring how clinicians can assess the level of adjustment in girls and their 
families may be of use. Although the current study provides useful insight into the impact of TS on girls’ 
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identity and sense of self, future research to fully explore the effect of TS on identity in both adolescents 
and adult women with TS may be helpful.  
 
Conclusions 
This research has provided an in-depth account of the experience of diagnostic disclosure and the 
tendency to avoid disclosure to others, from the perspectives of girls with TS and their parents/guardians. 
The study has also highlighted variations in the level of impact of TS across families. Recommendations 
for clinical practice include explicitly discussing infertility with girls and their families and emphasising 
the importance of open, honest communication. Future research to further explore how to enable girls to 
disclose their diagnosis to others may be of use.   
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Appendices 
 
Appendix 1.1 Guidelines for submission to the British Journal of Health Psychology 
Title Page 
You may like to use this template for your title page. The title page should contain: 
• A short informative title containing the major key words. The title should not contain abbreviations 
(see Wiley's best practice SEO tips); 
• A short running title of less than 40 characters; 
• The full names of the authors; 
• The author's institutional affiliations where the work was conducted, with a footnote for the author’s 
present address if different from where the work was conducted; 
• Abstract; 
• Keywords; 
• Data availability statement (see Data Sharing and Data Accessibility Policy); 
• Acknowledgments. 
Authorship 
Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for 
details on author listing eligibility. When entering the author names into Editorial Manager, the corresponding 
author will be asked to provide a CRediT contributor role to classify the role that each author played in 
creating the manuscript. Please see the Project CRediT website for a list of roles. 
Abstract 
For articles containing original scientific research, a structured abstract of up to 250 words should be included 
with the headings: Objectives, Design, Methods, Results, Conclusions. Review articles should use these 
headings: Purpose, Methods, Results, Conclusions. As the abstract is often the most widely visible part of 
your paper, it is important that it conveys succinctly all the most important features of your study. You can 
save words by writing short, direct sentences. Helpful hints about writing the conclusions to abstracts can be 
found here. 
Keywords 
Please provide appropriate keywords. 
Acknowledgments 
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission 
from the contributor, in an Acknowledgments section. Financial and material support should also be 
mentioned. Thanks to anonymous reviewers are not appropriate. 
 
Statement of Contribution 
All authors are required to provide a clear summary of ‘what is already known on this subject?’ and ‘what 
does this study add?’. Authors should identify existing research knowledge relating to the specific research 
question and give a summary of the new knowledge added by your study. Under each of these headings, 
please provide 2-3 (maximum) clear outcome statements (not process statements of what the paper does); 
the statements for 'what does this study add?' should be presented as bullet points of no more than 100 
characters each. The Statement of Contribution should be a separate file. 
 
Main Text File 
As papers are double-blind peer reviewed, the main text file should not include any information that might 
identify the authors. 
The main text file should be presented in the following order: 
• Title 
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• Main text 
• References 
• Tables and figures (each complete with title and footnotes) 
• Appendices (if relevant) 
Supporting information should be supplied as separate files. Tables and figures can be included at the end of 
the main document or attached as separate files but they must be mentioned in the text. 
• As papers are double-blind peer reviewed, the main text file should not include any information that 
might identify the authors. Please do not mention the authors’ names or affiliations and always refer to 
any previous work in the third person. 
• The journal uses British spelling; however, authors may submit using either option, as spelling of 
accepted papers is converted during the production process. 
References 
References should be prepared according to the Publication Manual of the American Psychological 
Association (6th edition). This means in text citations should follow the author-date method whereby the 
author's last name and the year of publication for the source should appear in the text, for example, (Jones, 
1998). The complete reference list should appear alphabetically by name at the end of the paper. Please note 
that for journal articles, issue numbers are not included unless each issue in the volume begins with page 1, 
and a DOI should be provided for all references where available. 
For more information about APA referencing style, please refer to the APA FAQ. 
Reference examples follow: 
Journal article 
Beers, S. R. , & De Bellis, M. D. (2002). Neuropsychological function in children with maltreatment-related 
posttraumatic stress disorder. The American Journal of Psychiatry, 159, 483–486. 
doi:10.1176/appi.ajp.159.3.483 
Book 
Bradley-Johnson, S. (1994). Psychoeducational assessment of students who are visually impaired or blind: 
Infancy through high school (2nd ed.). Austin, TX: Pro-ed. 
Internet Document 
Norton, R. (2006, November 4). How to train a cat to operate a light switch [Video file]. Retrieved from 
http://www.youtube.com/watch?v=Vja83KLQXZs 
Tables 
Tables should be self-contained and complement, not duplicate, information contained in the text. They 
should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – 
the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must 
be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be 
reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings. 
Figures 
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a 
wide variety of formats, sizes, and resolutions are accepted. 
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as 
well as the more detailed post-acceptance figure requirements. 
Legends should be concise but comprehensive – the figure and its legend must be understandable without 
reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of 
measurement. 
Colour figures. Figures submitted in colour may be reproduced in colour online free of charge. Please note, 
however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that 
they are legible if printed by a reader in black and white. If an author would prefer to have figures printed in 
colour in hard copies of the journal, a fee will be charged by the Publisher. 
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Appendix 1.2 Example of Full Search Strategy  
Exact subheadings and search terms varied slightly dependent on the Database; however, the table below 
provides an example.  
Database: Ovid Embase and Medline 
S1 Exp “Turner Syndrome” / all subheadings 
S2 Exp “sex chromosome abnormalities” / all subheadings 
S3 ((Turner* ADJ1 Syndrome*) or Bonnevie Ullrich* or Gonadal Dysgenes* or 
Monosomy* or (Ullrich* ADJ1 Turner*)).ti,ab  
S4 S1 or S2 or S3 
S5 Exp “Growth Hormone” / all subheadings  
S6 Exp “Human Growth Hormone” / all subheadings 
S7 (Growth Hormone* OR Somatropin* OR Somatotrop* OR Genotropin* OR 
Humatrope* OR Norditropin* OR Saizen* OR Zomacton* OR Nutropin* OR 
Omnitrop* OR Maxomat* OR Serostim* OR Cryo Tropin* OR Umatrope* OR 
Norditropin* hGH or rhGH).ti,ab 
S8 S5 or S6 or S7 
S9 Exp “Quality of life* or “Surveys and Questionnaires” or “Health status” or 
“Health status indicators” or “Activities of daily living” or “Health surveys” or 
“Quality adjusted life years” or “Treatment outcome” or “Psychometrics” / all 
subheadings 
S10 (Quality of life* or Life quality* or personal satisfact* or patient satisfact* or Happ* 
or self-concept* or Short form 36 or SF-36 or SF36 or QOL or Short form 12 or 
SF-12 or SF12 or HRQL or HRQOL or Euroqol or EQ-5D or Quality adjusted life 
year* or Quality of Wellbeing Index* or QALY or Health Utilities Index or Health 
stat* or Medical Outcomes Survey or (MOS)or Rosser or Health year equivalent* 
or HYE* or Ultilit* or Wellbeing* or Well being).ti,ab.   
S11 S9 or S10 
S12 Exp “Psychology” / all subheadings  
S13 (Psycholog* OR Psychosocial OR Outcome*).ti,ab. 
S14 S12 or 13 
S15 Exp “Adaptation Psychological” OR “Emotional Adjustment” OR “Social 
Adjustment” / all subheadings   
S16 (Adapt* OR Adjust* OR Behavio?r* OR Cope* OR Coping* OR Function* OR 
Emotion*).ti,ab. 
S17 S15 or 16 
S18 Exp “Mental Disorders” OR “Behavioral Symptoms” OR “Mental Health” / all 
subheadings  
S19 (Mood* OR Depress* OR Anxiet* OR Distress* OR Well-being* OR Wellbeing* 
OR Affect* Mental Health* OR Mental Disorder* OR Anxious* OR Mental 
Disease*).ti,ab. 
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S20 S18 or 19 
S21 S11 or S14 or S17 or S20 
S22 S3 AND S6 AND S21 
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Appendix 1.3 Data Extraction Sheet 
Systematic Review 
Turner Syndrome, Growth Hormone Therapy and Psychological Outcomes 
 
Data Extraction Sheet1 
 
Title: 
Authors: 
Journal: Year: 
Keywords: 
Aims: 
Study Design:  
Randomisation: 
Blinding:  
 
Sample: 
 
N: Mean age: Country: Gender: Ethnicity:  
Sample: Control Group: 
Number of Controls: 
Inclusion criteria: 
Exclusion criteria: 
 
Measures: 
 
Psychological outcomes: 
What was measured? (Constructs): 
Instrument: 
(1) Self-administered or (2) Experimenter Administered?: 
More than one psychological outcome measured: 
What was measured? (Constructs): 
Instrument: 
(1) Self-administered or (2) Experimenter Administered?: 
Other measures e.g. height: 
 
 
Interventions: 
 
What kind of growth hormone intervention did patients receive?: 
Intervention: e.g. rhGH or hGH: 
What was the dosage?:  
For how long?: 
 
Results: 
 
Main findings: 
 
 
1 Do not leave any blank space. If it is not applicable, write “N/A”. If there is no comment, write “None”. 
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Follow up duration: 
Author’s Interpretations: 
 
Author’s Limitations: 
 
Reviewers’ Limitations: 
 
 
Other comments: 
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Appendix 1.4 Quality Appraisal Tool 
Crowe Critical Appraisal Tool (CCAT) Form (v1.4) Reference   Reviewer   
 
 This form must be used in conjunction with the CCAT User Guide (v1.4); otherwise validity and reliability may be severely compromised.  
 
         
 
Citation         
 
       Year  
 
         
        
 
Research design (add if not listed)        
 
Not research Article | Editorial | Report | Opinion | Guideline | Pamphlet | …     
 
          
Historical …        
 
       
Qualitative Narrative | Phenomenology | Ethnography | Grounded theory | Narrative case study | …     
 
        
Descriptive, A. Cross-sectional | Longitudinal | Retrospective | Prospective | Correlational | Predictive | …     
 
Exploratory, 
        
 
B. Cohort | Case-control | Survey | Developmental | Normative | Case study | … 
    
 
Observational     
 
     
 True Pre-test/post-test control group | Solomon four-group | Post-test only control group | Randomised two-factor |  
 
 experiment Placebo controlled trial | …       
 
      
Experimental 
Quasi- Post-test only | Non-equivalent control group | Counter balanced (cross-over) | Multiple time series |  
 
experiment Separate sample pre-test post-test [no Control] [Control] | … 
    
 
     
 
     
 Single One-shot experimental (case study) | Simple time series | One group pre-test/post-test | Interactive | Multiple baseline |  
 
 system Within subjects (Equivalent time, repeated measures, multiple treatment) | …     
 
 
 
Mixed Methods  Action research | Sequential | Concurrent | Transformative | … 
 
 
Synthesis Systematic review | Critical review | Thematic synthesis | Meta-ethnography | Narrative synthesis | …    
 
                
Other …           
 
                
               
 
Variables and analysis              
 
Intervention(s), Treatment(s), Exposure(s) Outcome(s), Output(s), Predictor(s), Measure(s) Data analysis method(s)    
 
                
               
 
               
 
Sampling              
 
Total size 
  Group 1  Group 2  Group 3  Group 4   Control   
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Population,  
sample, 
 
setting 
 
 
Data collection (add if not listed) 
 
 a) Primary | Secondary | …  a) Formal | Informal | … 
Audit/Review b) Authoritative | Partisan | Antagonist | … Interview b) Structured | Semi-structured | Unstructured | … 
 c) Literature | Systematic | …  c) One-on-one | Group | Multiple | Self-administered | … 
    
 a) Participant | Non-participant | …  a) Standardised | Norm-ref | Criterion-ref | Ipsative | … 
Observation b) Structured | Semi-structured | Unstructured | … Testing b) Objective | Subjective | … 
 c) Covert | Candid | …  c) One-on-one | Group | Self-administered | … 
    
 
 
Scores 
 
Preliminaries  Design  Data Collection  Results  Total [/40]   
           
Introduction  Sampling  Ethical Matters  Discussion  Total [%]   
           
           
General notes           
           
Crowe Critical Appraisal Tool (CCAT) :: Version 1.4 (19 November 2013) :: Michael Crowe (michael.crowe@my.jcu.edu.au)  Page 1 of 2  
 
 
This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/3.0/ 
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Appraise research on the merits of the research design used, not against other research designs. 
 
 
 Category  Item descriptors Description  Score  
 
 Item  [  Present;    Absent; ■ Not applicable] [Important information for each item]  [0–5]  
 
          
 1. Preliminaries        
 
 Title  1. Includes study aims   and design     
 
 
Abstract 
 
1. Key information 
     
      
 
 
(assess last) 
 2. Balanced   and informative     
 
        
 
 
Text 
 
1. Sufficient detail others could reproduce 
     
      
 
 
(assess last) 
 2. Clear/concise writing  , table(s)  , diagram(s)  , figure(s)     
 
        
 
     Preliminaries [/5]    
 
 2. Introduction        
 
 Background  1. Summary of current knowledge     
 
   2. Specific problem(s) addressed   and reason(s) for addressing     
 
 
Objective 
 
1. Primary objective(s), hypothesis(es), or aim(s) 
     
      
 
   2. Secondary question(s)     
 
   Is it worth continuing? Introduction [/5]    
 
 3. Design        
 
 Research design  1. Research design(s) chosen   and why     
 
   2. Suitability of research design(s)     
 
 
Intervention, 
 
1. Intervention(s)/treatment(s)/exposure(s) chosen   and why 
     
      
 
 
Treatment, Exposure 
 2. Precise details of the intervention(s)/treatment(s)/exposure(s)   for each group     
 
  
3. Intervention(s)/treatment(s)/exposure(s) valid   and reliable 
    
 
       
 
 
Outcome, Output, 
 
1. Outcome(s)/output(s)/predictor(s)/measure(s) chosen   and why 
     
      
 
 
Predictor, Measure 
 2. Clearly define outcome(s)/output(s)/predictor(s)/measure(s)     
 
  
3. Outcome(s)/output(s)/predictor(s)/measure(s) valid   and reliable 
    
 
       
 
 
Bias, etc 
 
1. Potential bias  , confounding variables  , effect modifiers  , interactions 
     
      
 
   2. Sequence generation  , group allocation  , group balance  , and by whom     
 
   3. Equivalent treatment of participants/cases/groups     
 
   Is it worth continuing? Design [/5]    
 
 4. Sampling        
 
 Sampling method  1. Sampling method(s) chosen   and why     
 
   2. Suitability of sampling method     
 
 
Sample size 
 
1. Sample size  , how chosen  , and why 
     
      
 
   2. Suitability of sample size     
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 Sampling protocol  1. Target/actual/sample population(s): description   and suitability     
 
   2. Participants/cases/groups: inclusion   and exclusion   criteria     
 
   3. Recruitment of participants/cases/groups     
 
   Is it worth continuing? Sampling [/5]    
 
 5. Data collection        
 
 Collection method  1. Collection method(s) chosen   and why     
 
   2. Suitability of collection method(s)     
 
 
Collection protocol 
 
1. Include date(s)  , location(s)  , setting(s)  , personnel  , materials  , processes 
     
      
 
   2. Method(s) to ensure/enhance quality of measurement/instrumentation     
 
   3. Manage non-participation  , withdrawal  , incomplete/lost data     
 
   Is it worth continuing? Data collection [/5]    
 
 6. Ethical matters        
 
 Participant ethics  1. Informed consent  , equity     
 
   2. Privacy  , confidentiality/anonymity     
 
 
Researcher ethics 
 
1. Ethical approval  , funding  , conflict(s) of interest 
     
      
 
   2. Subjectivities  , relationship(s) with participants/cases     
 
   Is it worth continuing? Ethical matters [/5]    
 
 7. Results        
 
 Analysis, Integration,  1. A.I.I. method(s) for primary outcome(s)/output(s)/predictor(s) chosen   and why     
 
 
Interpretation method 
 2. Additional A.I.I. methods (e.g. subgroup analysis) chosen   and why     
 
  
3. Suitability of analysis/integration/interpretation method(s) 
    
 
       
 
 
Essential analysis 
 
1. Flow of participants/cases/groups through each stage of research 
     
      
 
   2. Demographic and other characteristics of participants/cases/groups     
 
   3. Analyse raw data  , response rate  , non-participation/withdrawal/incomplete/lost data     
 
 
Outcome, Output, 
 
1. Summary of results   and precision   for each outcome/output/predictor/measure 
     
      
 
 
Predictor analysis 
 2. Consideration of benefits/harms  , unexpected results  , problems/failures     
 
  
3. Description of outlying data (e.g. diverse cases, adverse effects, minor themes) 
    
 
       
 
     Results [/5]    
 
 8. Discussion        
 
 Interpretation  1. Interpretation of results in the context of current evidence   and objectives     
 
   2. Draw inferences consistent with the strength of the data     
 
   3. Consideration of alternative explanations for observed results     
 
   4. Account for bias  , confounding/effect modifiers/interactions/imprecision     
 
 
Generalisation 
 
1. Consideration of overall practical usefulness of the study 
     
      
 
   2. Description of generalisability (external validity) of the study     
 
 
Concluding remarks 
 
1. Highlight study’s particular strengths 
     
      
 
   2. Suggest steps that may improve future results (e.g. limitations)     
 
   3. Suggest further studies     
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     Discussion [/5]    
 
 9. Total        
 
 Total score  1. Add all scores for categories 1–8     
 
          
 
Total [/40]  
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Appendix 2.1 Letters of Approval 
NHS Board Approval 
Administrator: Mrs Elaine O’Neill 
 
 
 
 
Clinical Research & Development 
Telephone Number: 0141 314 4001 Dykebar Hospital, Ward 11 
E-Mail: elaine.o’neill2@ggc.scot.nhs.uk Grahamston Road 
Website: https://www.nhsggc.org.uk/about-
us/professional- Paisley, PA2 7DE 
   
Scotland, UK 
support-sites/research-
development/  
 
09 September 2019 
 
Ms Mhairi Nisbet 
Institute of Health and Wellbeing 
Admin Building 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 0XH 
 
NHS GG&C Board Approval 
Dear Ms M Nisbet, 
 
Study Title: 
 
 
Principal Investigator: 
 
GG&C HB site 
 
Sponsor 
 
A qualitative study exploring various aspects of disclosure in girls with Turner 
Syndrome: disclosure of the diagnosis to girls by their parents/professionals and girls 
experience of disclosing their condition to others. 
Ms Mhairi Nisbet 
 
The Royal Hospital for Children and Queen Elizabeth University Hospital 
 
NHS Greater Glasgow and Clyde 
69 
 
 
R&D reference: REC 
reference: Protocol 
no: (including version 
and date) 
 
GN19MG312 
 
19/WS/0132 
V2; 18/09/19
 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant Approval for the above 
study. 
Conditions of Approval 
1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial Regulations, 2004 a. 
During the life span of the study GGHB requires the following information relating to this site 
i. Notification of any potential serious breaches. 
ii. Notification of any regulatory inspections. 
 
It is your responsibility to ensure that all staff involved in the study at this site have the appropriate GCP 
training according to the GGHB GCP policy (www.nhsggc.org.uk/content/default.asp?page=s1411), evidence 
of such training to be filed in the site file. 
2. For all studies the following information is required during their lifespan: 
 
a. First study participant should be recruited within 30 days of approval date. 
b. Recruitment Numbers on a monthly basis 
c. Any change to local research team staff should be notified to R&D team 
d. Any amendments – Substantial or Non Substantial 
e. Notification of Trial/study end including final recruitment figures 
f. Final Report & Copies of Publications/Abstracts 
 
 
Please add this approval to your study file as this letter may be subject to audit and monitoring. 
Your personal information will be held on a secure national web-based NHS database. I wish 
you every success with this research study 
 
Yours sincerely, 
 
 
 
Mrs Elaine O’Neill 
Senior Research Administrator 
CC: Ms Emma-Jane Gault (University of Glasgow) 
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REC Approval 
 
WoSRES 
 
West of Scotland Research Ethics Service 
 
 
 
Miss Mhairi Nisbet West of Scotland REC 4 
Mental Health and Wellbeing Institute, University of   Ward 11 Dykebar Hospital 
Glasgow Grahamston Road 
Gartnavel Royal Hospital Paisley  
1055 Great Western Road PA2 7DE  
Glasgow   
G12 0XH Date 25 September 2019 
 Direct line 0141 314 0214 
 E-mail WoSREC4@ggc.scot.nhs.uk 
Dear Miss Nisbet   
Study title: A qualitative study exploring various aspects of 
 disclosure in girls with Turner Syndrome: disclosure of 
 the diagnosis to girls by their parents/professionals and 
 girls experience of disclosing their condition to others. 
REC reference: 19/WS/0132  
Protocol number: 1  
IRAS project ID: 263560  
 
Thank you for your email of 25 September 2019. I can confirm the REC has received the 
documents listed below and that these comply with the approval conditions detailed in our letter 
dated 25 September 2019. 
Documents received 
The documents received were as follows: 
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Document Version Date 
Participant information sheet (PIS) [PIS 16-25 yrs - tracked 
changes] 3 
25 September 
2019 
   
 
Approved documents 
The final list of approved documentation for the study is therefore as follows: 
 
Document Version Date 
Copies of advertisement materials for research participants 1 10 June 2019 
[Advertisement ]    
Interview schedules or topic guides for participants [Interview 1 10 June 2019 
Schedule]    
IRAS Application Form [IRAS_Form_07082019]  07 August 2019 
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Document Version Date 
Letter from funder [Proceed to Ethics letter (Univ of Glas)] N/A 28 May 2019 
    
Letters of invitation to participant [Letter of invitation 1 (To child)] 1 10 June 2019 
    
Letters of invitation to participant [Letter of invitation 2 (To 1 10 June 2019 
parent/guardian)]    
Other [University Insurance Document] N/A 24 July 2019 
    
Other [Assent Form 12-15 yrs] 1 18 
September 
2019 
    
Other [Responses to REC Provisional opinion] 1 18 
September 
2019 
    
Participant consent form [Consent form 12-15] 1 28 June 2019 
    
Participant consent form [16-25 and parent Consent Form] 1 28 June 2019 
    
Participant information sheet (PIS) [PIS 12-15 yrs_tracked 
changes] 2 18 
September 
2019 
    
Participant information sheet (PIS) [PIS 
parents/guardians_tracked 2 18 
September 
2019 
changes]    
Participant information sheet (PIS) [PIS 16-25 yrs - tracked 
changes] 3 25 
September 
2019 
    
Research protocol or project proposal [Protocol_tracked 
changes] 2 18 
September 
2019 
    
Summary CV for Chief Investigator (CI) [CI CV - Rory O'Connor]  01 March 2017 
    
Summary CV for student [Student CV - Mhairi Nisbet]  10 June 2019 
    
Summary CV for supervisor (student research) [Supervisor CV - 
Rory  01 March 2017 
O'Connor]    
Summary, synopsis or diagram (flowchart) of protocol in non 
technical 1 28 June 2019 
language [Recruitment Flowchart]    
 
You should ensure that the sponsor has a copy of the final documentation for the study. It is the sponsor's 
responsibility to ensure that the documentation is made available to R&D offices at all participating sites. 
 
19/WS/0132 Please quote this number on all correspondence 
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Yours sincerely 
 
 
 
 
 
Rozanne Suarez 
 
REC Manager 
Copy to: Professor Rory O’Connor, University of Glasgow 
 Emma-Jane Gault, University of Glasgow 
 nhsg.NRSPCC@nhs.net 
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Appendix 2.2 Participant Information Sheets 
12-15-year-old Participant Information Sheet 
                                               
 
Participant information sheet (Aged 12-15 years old) 
 
Study title 
A study looking into how girls with Turner Syndrome were told about their condition, and how they feel 
talking about their condition to other people.  
Invitation to take part   
You are invited to take part in a research project. We are looking for young people aged between 12-15 
years old who have been diagnosed with Turner Syndrome (TS) and their parents/guardians. Before 
deciding whether you want to take part or not it is important to understand why this research is being carried 
out. You also need to know what taking part will involve. This information is written below. Please take the 
time to read this carefully and, if you’d like, talk about it with others. If there is anything that is not clear or 
you would like more information on, please feel free to ask. Take time to decide whether you would like to 
take part. 
If you decide to take part in this study, please contact one of the researchers, using the contact details 
below. If you attend the Turner Syndrome clinic in Glasgow, Dr Mason will also ask you and your 
parent/guardian if you would like to take part the next time you attend. You will be given a copy of this 
Participant Information Sheet and the signed consent form to keep. Thank you for taking the time to read 
this information sheet. 
Who is conducting the research? 
The research is being carried out by Mhairi Nisbet (Trainee Clinical Psychologist), Professor Rory O’Connor 
(Professor of Health Psychology), Dr Avril Mason (Consultant Endocrinologist), Dr Marie Freel (Consultant 
Endocrinologist) and Dr Elizabeth Hunter (Clinical Psychologist). The study is being carried as part of Mhairi 
Nisbet’s training course at the University of Glasgow. 
What is the purpose of the study? 
This study is looking at how girls with Turner Syndrome (TS) were told about their condition. We know that 
TS is quite a common genetic condition. Some girls are diagnosed when they are a baby, while others are 
diagnosed when they are a child or teenager.  
The study will look at how girls found out they had TS, what they feel comfortable telling others about their 
condition and their parent/guardians experience of talking about TS with their daughters. The aim of this 
study is to gain a better understanding about the best way to tell families and young people about TS for the 
first time.  
Why have I been invited to take part? 
You have been invited to take part because you have TS and are aged between 12-15 years old.  
What would taking part involve? 
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If you decide to take part, you will be contacted by Mhairi Nisbet to arrange a good time to attend either the 
Royal Hospital for Children, Glasgow or the Area G clinics within the Queen Elizabeth University Hospital, 
Glasgow. You should come with at least one of your parents/guardians. If you already attend one of the TS 
clinics in Glasgow, then we’ll try to invite you on the same day as you are attending the TS clinic anyway. If 
this doesn’t work for you then we will arrange another date that suits you and your parent/guardian. If we 
arrange a date that’s different from when you would usually attend the clinic, you will be reimbursed for any 
travel expenses.  
If you don’t attend one of the Glasgow TS clinics, then we will arrange a day and time that suits you to come 
along to one of the hospitals above. We will reimburse you for any travel expenses.  
The research visit will last around about one hour in total. The first thing we will do is ask you and at least 
one of your parents/guardians to sign a form to say you are both happy for you to take part in the study. You 
and your parent/guardian will also have the chance to ask any more questions. 
Then we will ask you and your parent/guardian some questions about how you found out you had TS, and 
how you feel talking about your condition with other people. We’ll also ask about what having a diagnosis of 
TS means to you. 
Sometimes young people don’t want to talk about certain subjects in front of their parents. We will ask your 
parent/guardian to wait outside the room while we ask you if there is anything else you would like to talk 
about or add. We will then ask you to wait outside and ask your parent/guardian if there is anything else 
they’d like to talk about. If not, the interview will be finished. With your permission, your interview will be 
recorded using an audio recorder, so we remember everything that you tell us. All information will be 
confidential.  
What are the possible benefits of taking part? 
The advantages of taking part are mainly around helping us to get a better understanding of what it’s like 
talking about TS for the first time, and what it’s like to live with TS. This is so we can help others with TS in 
the future. There are no direct benefits to taking part in the study.  
What are the possible disadvantages and risks of taking part? 
It’s possible you might feel upset when talking about your experience of having TS and the impact it’s had 
on you and your family. If this happens then the interview will be paused, and you will be offered support 
from the Trainee Clinical Psychologist doing the interview, or another Clinical Psychologist. You can also 
spend some time talking to your parent/guardian alone about how you feel.  
If you feel okay to continue, the interview will carry on. If you decide you don’t want to then the interview will 
stop. There are no other risks to taking part.  
Do I have to take part? 
No, you don’t. It is your choice if you want to take part and you can always change your mind. You don’t 
have to answer any questions that you don’t want to.  Just tell your parent/guardian and the people carrying 
out the research that you don’t want to take part any more. You don’t have to give a reason. It is your 
choice. 
Will my information be confidential? 
All personal information collected about you during the study will be kept completely confidential.  If any 
information about you was required to leave the hospital, your name and address will be removed so that 
you can’t be recognised from it. 
What happens to my information? 
We may be collecting and keeping personal information from you to do this study. Information will be 
anonymised and stored within a locked filing cabinet in the locked Psychology Department or in ‘OneDrive 
for Business’, one of the University of Glasgow’s secure storage providers, on a password protected 
computer. This means data will be held on University computer systems and premises but that data held on 
University computers will be anonymised with the code linking to identifiable information held separately. 
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Researchers from the University of Glasgow collect, store and process all personal information in line with 
the General Data Protection Regulation (2018) and the Data Protection Act (2018). This means that it will be 
stored securely and not shared with other people unless you say so. If any findings from this study are 
published, your name and any other information which means someone could recognise you will not be 
included. This means no one will be able to tell it’s you. However, we might use direct quotes in the final 
report, as examples of the kinds of topics we talk about during the interview.  
NHS Greater Glasgow and Clyde is the sponsor for this study based in Scotland. We will be using 
information from you in order to undertake this study and will act as the data controller for this study. This 
means that we are responsible for looking after your information and using it properly. NHS Greater 
Glasgow and Clyde will keep identifiable information about you for 10 years after the study has finished. 
Your rights to access, change or move your information are limited, as we need to manage your information 
in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will 
keep the information about you that we have already obtained. To safeguard your rights, we will use the 
minimum personally-identifiable information possible. 
You can find out more about how we use your information by contacting Professor O’Connor and/or at: 
https://www.nhsggc.org.uk/patients-and-visitors/faqs/data-protection-privacy/.       
 
What will happen to the results of the study? 
At the end of the study, the finished report will be handed in to the University of Glasgow. We hope that the 
findings will be published in a medical journal or may be presented at a conference. This is to make sure 
other researchers and clinicians working with girls with TS know what we have found. If you like, you will be 
sent a written summary of the report of the findings in plain English. This will be easier to read. Your identity 
and personal information will not be reported or published following this study. 
Who is funding the research? 
The research is funded by the Clinical Psychology course at the University of Glasgow. 
Who has reviewed the study? 
The study has been reviewed by Glasgow University to make sure that it meets the necessary standards. 
The West of Scotland Research Ethics Committee 4 board has also reviewed this study to make sure it 
meets ethical standards. 
Thank you very much for taking the time to read this Information Sheet. 
 
Contact details 
If you have any questions you can contact the research team who will be carrying out the research: 
Mhairi Nisbet (Trainee Clinical Psychologist) 
Email: 0901173n@student.gla.ac.uk 
Tel: 07743304734 
 
Professor Rory O’Connor (Professor of Health Psychology) 
Email: rory.oconnor@glasgow.ac.uk 
Tel: (0)141 211-0690/3927 
 
Dr Avril Mason (Consultant in Paediatric Endocrinology) 
Email: avrilmason@nhs.net 
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Tel: 0141 201 0000 
 
Dr Marie Freel (Clinical Senior Lecturer in Diabetes and Endocrinology) 
Email: marie.freel@glasgow.ac.uk 
Tel: 0141 451 6189 
 
Dr Elizabeth Hunter (Clinical Psychologist) 
Email: Elizabeth.Hunter2@ggc.scot.nhs.uk 
Tel: 0141 451 661 
 
 
16-25-year-old/Parent and Guardian Participant Information Sheet 
 
                                            
 
 
Participant information sheet (Aged 16-25 years old)/(Parent/Guardian) 
 
Study title 
A qualitative study exploring various aspects of disclosure in girls with Turner Syndrome: disclosure of the 
diagnosis to girls by their parents/professionals and girls experience of disclosing their condition to others.   
Invitation to take part   
You are invited to take part in a research project. We are looking for young people aged between 16-25 
years old/12-25 years old who have been diagnosed with Turner Syndrome (TS) and their 
parents/guardians. Before deciding whether you want to take part or not it is important to understand why 
this research is being carried out. You also need to know what taking part will involve. This information is 
written below. Please take the time to read this carefully and, if you’d like/if you wish, talk about it with 
others. If there is anything that is not clear or you would like more information on, please feel free/do not 
hesitate to ask. Take time to decide whether you would like to take part. 
If you decide to take part in this study, please contact one of the researchers using the contact details 
below. If you/your daughter attend’s one of the Turner Syndrome clinics in Glasgow then Dr Mason or Dr 
Freel will also ask you and your parent/guardian if you would like to take part the next time you attend. If you 
usually attend this appointment with your daughter, you will also be asked if you would like to take part.  You 
will be given a copy of this Participant Information Sheet and the signed consent form to keep. Thank you 
for taking the time to read this information sheet. 
Who is conducting the research? 
The research is being carried out by Mhairi Nisbet (Trainee Clinical Psychologist), Professor Rory O’Connor 
(Professor of Health Psychology), Dr Avril Mason (Consultant Endocrinologist), Dr Marie Freel (Consultant 
Endocrinologist) and Dr Elizabeth Hunter (Clinical Psychologist). The study is being carried as part of Mhairi 
78 
 
Nisbet’s training course at the University of Glasgow/the University of Glasgow’s Doctorate in Clinical 
Psychology degree course. 
What is the purpose of the study? 
This study is looking at/investigating how girls with Turner Syndrome (TS) were told about their condition. 
We know that TS is a fairly common genetic condition. Some girls are diagnosed when they are a baby, 
while others are diagnosed when they are a child or teenager.  
The study will look at how girls found out they had TS, what they feel comfortable telling others about their 
condition and their parent/guardians experience of talking about/discussing TS with their daughters. The aim 
of this study is to gain a better understanding about the best way to tell families and young people about TS 
for the first time.  
Why have I been invited to take part? 
You have been invited to take part because you have TS and are aged between 16-25 years old. You have 
been invited to take part because your child has the condition Turner Syndrome and she is aged between 
12-25 years old. This study aims to explore how girls learned they had TS and your experience of this as a 
parent/guardian.  
What would taking part involve? 
If you decide to take part, you/and your daughter will be contacted by Mhairi Nisbet to arrange a good time 
to attend the Royal Hospital for Children, Glasgow or the Area G clinics within the Queen Elizabeth 
University Hospital, Glasgow. You should come with at least one of your parents/guardians. If you/your 
daughter already attend one of the TS clinics in Glasgow, then we’ll try to invite you both on the same day 
as you are attending the TS clinic anyway. If this doesn’t work for you/isn’t suitable then we will arrange 
another date that suits you both. If we arrange a date that’s different from when you/your daughter would 
usually attend the clinic, you will be reimbursed for any travel expenses.  
If you/your daughter don’t attend one of the Glasgow TS clinics, then we will arrange a day and time that 
suits you to come along to one of the hospitals/locations above. We will reimburse you for any travel 
expenses. We hope to interview girls with at least one parent/guardian. 
The research visit will last around about one hour in total. The first thing we will do is ask you to sign a form 
to say that you are happy to take part in the study. We will also ask your parent/guardian to sign a form to 
say they are happy to take part in the study. We will also ask your daughter to sign a form to say she is 
happy to take part, and if she is under the age of 16 you will be required to sign her consent form. You and 
your parent/guardian/daughter will also have the chance to ask any more questions. 
Then we will ask you and your parent/guardian/daughter some questions about how you/she found out 
you/she had TS, and how you/she feel talking about your/her condition with others. We’ll also ask about 
what having a diagnosis of TS means to you/your daughter and your family. 
Sometimes young people don’t want to talk about certain subjects in front of their parents. We will ask your 
parent/guardian/you to wait outside the room while we ask you/your daughter if there is anything else 
you/she would like to talk about or add. We will then ask you/her to wait outside and ask your 
parent/guardian/you if there is anything else they’d/you like to talk about. If not, the interview will be finished. 
With your permission, your interview will be recorded using an audio recorder, so we remember everything 
that you tell us. All information will be confidential.  
What are the possible benefits of taking part? 
The advantages of taking part are mainly around helping us to get a better understanding of what it’s like 
talking about TS for the first time, and what it’s like to live with TS. This is so we can help others with TS in 
the future. There are no direct benefits to taking part in the study. 
What are the possible disadvantages and risks of taking part? 
It’s possible you/or your daughter might feel upset when talking about your/the experience of having TS and 
the impact it’s had on you and your family. If this happens then the interview will be paused, and you will be 
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offered support from the Trainee Clinical Psychologist doing the interview or another Clinical Psychologist. 
You can also spend some time talking to your parent/guardian/daughter alone about how you feel.  
If you both feel okay to continue, the interview will carry on. If you decide you don’t want to then the 
interview will stop. There are no other risks to taking part.  
Do I have to take part? 
No, you don’t. It is your choice if you want to take part and you can always change your mind. You don’t 
have to answer any questions that you don’t want to.  Just tell the people carrying out the research that you 
don’t want to take part any more. You don’t have to give a reason. It is your choice. 
Will my information be confidential? 
All information collected about you during the study will be kept completely confidential. If any information 
about you was required to leave the hospital, your name and address will be removed so that you can’t be 
recognised from it. Please note that assurances on confidentiality will be strictly adhered to unless we think 
you or someone else is at risk. In such cases, the University may be obliged to contact relevant statutory 
bodies/agencies. 
What happens to my information? 
We may be collecting and keeping personal information from you to do this study. Information will be 
anonymised and stored within a locked filing cabinet in the locked Psychology Department or in ‘OneDrive 
for Business’, one of the University of Glasgow’s secure storage providers, on a password protected 
computer. This means data will be held on University computer systems and premises, but that data held on 
University computers will be anonymised with the code linking to identifiable information held separately. 
Researchers from the University of Glasgow collect, store and process all personal information in line with 
the General Data Protection Regulation (2018) and the Data Protection Act (2018). This means that it will be 
stored securely and not shared with other people unless you say so. If any findings from this study are 
published, your name and any other information which means someone could recognise you will not be 
included. This means no one will be able to tell it’s you. However, we might use direct quotes in the final 
report, as examples of the kinds of topics we talk about during the interview.  
NHS Greater Glasgow and Clyde is the sponsor for this study based in Scotland. We will be using 
information from you in order to undertake this study and will act as the data controller for this study. This 
means that we are responsible for looking after your information and using it properly. NHS Greater 
Glasgow and Clyde will keep identifiable information about you for 10 years after the study has finished. 
Your rights to access, change or move your information are limited, as we need to manage your information 
in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will 
keep the information about you that we have already obtained. To safeguard your rights, we will use the 
minimum personally-identifiable information possible. 
You can find out more about how we use your information by contacting Professor O’Connor and/or at: 
https://www.nhsggc.org.uk/patients-and-visitors/faqs/data-protection-privacy/.       
What will happen to the results of the study? 
At the end of the study, the finished report will be handed in to the University of Glasgow. We hope that the 
findings will be published in a medical journal or may be presented at a conference. This is to make sure the 
general public other researchers and clinicians working with girls with TS know what we have found. If you 
like/wish, you will be sent a written summary of the report of the findings in plain English. This will be easier 
to read. Your identity and personal information will not be reported or published following this study. 
Who is funding the research? 
The research is funded by the Clinical Psychology course at the University of Glasgow. 
Who has reviewed the study? 
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The study has been reviewed by Glasgow University to make sure that it meets the necessary standards. 
The West of Scotland Research Ethics Committee 4 board has also reviewed this study to make sure it 
meets ethical standards. 
Thank you very much for taking the time to read this Information Sheet. 
 
Contact details 
If you have any questions you can contact the research team who will be carrying out the research: 
Mhairi Nisbet (Trainee Clinical Psychologist) 
Email: 0901173n@student.gla.ac.uk 
Tel: 07743304734 
 
Professor Rory O’Connor (Professor of Health Psychology) 
Email: rory.oconnor@glasgow.ac.uk 
Tel: (0)141 211-0690/3927 
 
Dr Avril Mason (Consultant in Paediatric Endocrinology) 
Email: avrilmason@nhs.net 
Tel: 0141 201 0000 
 
Dr Marie Freel (Clinical Senior Lecturer in Diabetes and Endocrinology) 
Email: marie.freel@glasgow.ac.uk 
Tel: 0141 451 6189 
 
Dr Elizabeth Hunter (Clinical Psychologist) 
Email: Elizabeth.Hunter2@ggc.scot.nhs.uk 
Tel: 0141 451 661 
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Appendix 2.3 Consent forms  
12-15-year-old consent form 
                                                                       
 
Centre Number:  
Project Number:  
Participant Identification Number for this trial:  
Title of Project:  
 
 
 
A qualitative study exploring various aspects of disclosure in girls with Turner 
Syndrome: disclosure of the diagnosis to girls by their parents/professionals and 
girls experience of disclosing their condition to others.   
 
Name of Researcher(s): Mhairi Nisbet 
 
 
CONSENT FORM Please 
initial box 
I’ve had the chance to read and think about the information in the Participant Information 
Sheet for girls aged 12-15 years old (Version 2 dated 18/07/19).  
I’ve had the chance to think about the information and ask any questions I might have had and 
understand the answers I have been given.   
I understand it’s up to me if I want to take part and that I can decide not to take part at any 
time, without giving any reason, without my legal rights being affected.  
I confirm that I agree to the way my data will be collected (through doing the interview) and 
processed and that data will be stored for up to 10 years in the University in line with relevant 
Data Protection policies and regulations.  
 
I understand that all data and information I provide will be kept confidential and will be seen 
only by study researchers and regulators whose job it is to check the work of researchers.   
I agree that my name, contact details and data described in the information sheet will be kept 
for the purposes of this research project.  
I understand that if I decide to stop taking part, my data collected up to then will be kept and 
used for the remainder of the study.  
 
I agree to my interview being audio-recorded.   
I understand that the recorded interview will be transcribed (typed out) word by 
word and the transcription stored for up to 10 years in the University in line with 
Data Protection policies and regulations. 
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I understand that my information and things that I say in an interview might be 
quoted in reports and articles that are published about the study, but my name or 
anything else that could tell people who I am will not be revealed. 
 
  I agree to take part in the study. 
 
 
 
 
 
           
Name of participant Date Signature 
 
 
 
 
    
Name of participant’s  
parent/guardian  Date Signature 
 
 
 
   
Researcher Date Signature 
 
(1 copy for participant; 1 copy for researcher) 
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16-25-year-old/Parent and Guardians consent form 
 
                                                                  
 
Centre Number:  
Project Number:  
Participant Identification Number for this trial:  
Title of Project:  
 
 
 
A qualitative study exploring various aspects of disclosure in girls with Turner 
Syndrome: disclosure of the diagnosis to girls by their parents/professionals and 
girls experience of disclosing their condition to others.   
 
 
Name of Researcher(s): Mhairi Nisbet 
 
 
CONSENT FORM Please 
initial box 
I confirm that I have read and understood the Participant Information Sheet for either girls 
aged 16-25 (Version 3 dated 25/09/19) or for parents/guardians (Version 2 dated 18/09/19).  
I have had the opportunity to think about the information and ask questions, and understand 
the answers I have been given.   
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my legal rights being affected.  
I confirm that I agree to the way my data will be collected and processed and that data will be 
stored for up to 10 years in University archiving facilities in accordance with relevant Data 
Protection policies and regulations.  
 
I understand that all data and information I provide will be kept confidential and will be seen 
only by study researchers and regulators whose job it is to check the work of researchers.   
I agree that my name, contact details and data described in the information sheet will be kept 
for the purposes of this research project.  
I understand that if I withdraw from the study, my data collected up to that point will be 
retained and used for the remainder of the study.  
 
I agree to my interview being audio-recorded.  
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I understand that the recorded interview will be transcribed word by word and the 
transcription stored for up to 10 years in University archiving facilities in 
accordance with Data Protection policies and regulations. 
 
I understand that my information and things that I say in an interview may be 
quoted in reports and articles that are published about the study, but my name or 
anything else that could tell people who I am will not be revealed. 
 
  I agree to take part in the study. 
 
 
 
 
 
           
Name of participant Date Signature 
 
Parent/guardian of: 
(if applicable)  
 
 
 
 
   
Researcher Date Signature 
 
(1 copy for participant; 1 copy for researcher) 
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Appendix 2.4 Interview Schedule 
A. (Topic) diagnostic narrative 
Opening Questions:  
Girls with TS: 
1. Can you tell me a bit about how long you’ve been coming to the clinic? 
2. Can you tell me a bit about how you found out you had Turner Syndrome? 
Parent/guardian: 
3. Where you involved in telling (participant) they had Turner Syndrome? 
4. Can you tell me how you found telling (participant) about the aspects of their condition? 
5. Do you have anything to add around (participants) diagnosis? 
Prompts:  
• How old were you when you received your diagnosis? 
• What do you remember being told about your diagnosis? 
• What was good about it? 
• What could have been better? 
• Did you suspect that you were not given information about TS? 
 
B. (Topic) aspects of the condition 
Opening questions: 
Girls with TS: 
6. Can you tell me what having TS means for you? 
7. Do you have any health problems relating to TS? 
 
Prompts:  
• Do you know of any other health problems that others with TS might have? 
 
 
C. (Topic) what is disclosed to others e.g. peers 
Opening question: 
Girls with TS: 
8. How do you feel talking about your condition to others? 
 
Prompts: 
• Who do you feel comfortable talking about it with? 
• What aspects are easier to talk about? 
• What aspects are harder to talk about? 
• What would be your worries around talking about your condition to others? 
 
 
D. (Topic) advice around disclosure 
Opening questions: 
Girls with TS: 
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9. What advice would you give to girls that have been diagnosed when talking about their condition to 
others? 
Parent/guardian: 
10. What advice would you give to parents talking to their daughter about TS? 
Both girls with TS and parent/guardian: 
11. What advice would you give to HCP’s talking to a girl with TS at diagnosis and beyond?  
 
E. (Topic) Impact 
Opening question: 
Girls with TS: 
12. Has having TS had any impact on you and your life? 
Both girls with TS and parent/guardian: 
13. Do you think your TS diagnosis has had an impact on your family?  
 
Prompts: 
• How does this impact you day to day?  
• Has it affected your relationships e.g. with friends?  
• How does this impact your family day to day? 
 
F. Opportunity to speak without parent/guardian/daughter present 
Opening question: 
14. Are there any topics you’d like to talk about again?  
15. Is there anything else you’d like to add?  
 
If no: 
 
Closing  
Do you have any further questions?  
Thank you very much for taking part. 
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Appendix 2.5 Example of coding and analysis 
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Appendix 2.6 Project Proposal 
A qualitative study exploring various aspects of disclosure in girls with Turner Syndrome: disclosure of the 
diagnosis to girls by their parents/professionals and girls experience of disclosing their condition to others. 
   
Abstract  
Background 
Turner syndrome (TS) is a genetic condition occurring in around 1/2500 female births. Although most girls 
are diagnosed by adolescence, a previous study found 45/322 participants were unaware of their TS 
diagnosis. Preliminary research suggests parents may withhold information from their daughters, particularly 
around the infertility component. Current literature around TS and disclosure is limited and has not yet 
investigated the impact of having TS on the girls and their families.  
Aims 
The primary aim of this study is to explore the nature of disclosure in girls with TS; disclosure of the 
diagnosis to girls by their parents/professionals and girls experience of disclosing their condition to others. 
The secondary aim is to explore whether TS has had an impact on girls and their family’s lives. 
Methods 
This study shall be qualitative in nature, to gain a fuller insight into the nature of disclosure in girls with TS. 
Semi structured qualitative interviews will be conducted with both girls and their parents.  
Applications 
We hope this project could provide further recommendations for parents and professionals about factors 
that facilitate disclosure in girls with TS. It may also highlight the potential barriers to parents disclosing 
aspects of the condition to their children.  
 
Introduction  
Turner Syndrome 
Turner syndrome (TS) is a genetic condition resulting from a sex chromosome anomaly that occurs in 
approximately 1/2000 to 1/2500 live female births (Apperley et al., 2018). The condition is most often 
caused by the absence of all or part of the second sex chromosome. Typically, women with TS exhibit short 
stature, reproductive, cardiovascular, endocrine, renal, vision and/or hearing abnormalities (Morgan, 2007; 
Bondy, 2014). Research also suggests women with TS experience psychosocial difficulties in areas such as 
social skills, self-esteem and perceptions of competence, compared to their peers (Reimann et al., 2018). 
Most girls are diagnosed with the condition by the time they reach adolescence, however the time of 
diagnosis can vary from the second trimester of pregnancy through to adulthood (Apperley et al., 2018).  
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Disclosure to children with disabilities/illnesses 
Historically, research suggests clinicians took a ‘protective approach’ when communicating diagnosis and 
prognosis to children, the rationale being that patients should be shielded from distress (Sisk et al., 2016). 
However as objective evidence has accumulated, a more open approach has been recommended, taking 
hope and prognosis (Mack et al., 2006), individual differences e.g. developmental stage (Bluebond-Langner, 
Belasco and DeMesquita Wander, 2010) and family culture (Bluebond-Langner et al., 2007) into 
consideration.   
While most studies focus on children with intellectual disabilities, HIV or cancer, there appears to be less 
research exploring disclosure in children with genetic conditions. Hill, Sahhar, Aitken, Savarirayan, & 
Metcalfe, (2003) conducted qualitative research to explore parents experience of being told their child had 
bone dysplasia which results in significantly short stature. They found the way in which the diagnosis is 
explained to be the most important thing to parents, including factors such as having written information 
around the condition, potential medication complications and how to access support. Dennis, Howell, 
Cordeiro, & Tartaglia, (2015) surveyed the parents of and individuals with a sex chromosome aneuploidy 
affecting fertility, and found that both groups valued full, early disclosure.   
Poor disclosure or withholding a diagnosis appears to result in a number of negative consequences for both 
children and their families. Research exploring children with a diagnosis of cancer found that poor 
communication between clinicians parents and children can increase the suffering of patients and their 
families (Sisk et al., 2016). Gaff & Bylund (2010) noted that if a diagnosis is withheld it could expand into a 
family secret, resulting in an environment of distrust and strain amongst family interpersonal relationships. 
An atmosphere of secrecy might also dissuade children from asking questions; Metcalfe, Plumridge, Coad, 
Shanks, & Gill (2011) found that if parents did not acknowledge that their child had a genetic condition then 
siblings of the affected child felt inhibited from asking questions because they did not want to upset their 
parents.  
Turner Syndrome and Disclosure 
Gravholt et al., (2003) conducted a study that assessed the characteristics and risk factors of bone fractures 
in women with TS (average age 30 years old). Unexpectedly, they discovered 45/322 participants they 
surveyed were unaware of their TS diagnosis. Further qualitative research by Sutton et al., (2005) explored 
the challenges experienced by 97 girls and women with TS across the lifespan, ranging from 7-59 years of 
age. The average age of diagnosis was 12 years old; however, they found many participants had some 
aspect of the TS diagnosis kept secret from them. Secondary analysis examining the impact of secret-
keeping on girls and women with TS suggests that parents are the most likely individuals to withhold 
diagnostic information from their daughters, particularly the infertility component (Sutton et al., 2006). Sutton 
et al., (2006) found patients with TS from whom information was withheld about their condition were at 
higher risk of depression and generally mistrusted health care professionals. 
A recent cross sectional study from King, Plamondon, Counts, Laney, & Dixon, (2016b) explored the timing 
for parents to discuss infertility with their daughters with a diagnosis of TS and the potential barriers that 
hinder their ability to facilitate this conversation. They found that age and emotional maturity were key 
factors in determining when parents would choose to discuss infertility. Being afraid of negative emotion and 
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struggling with the balance of educating plus protecting their daughters were two of the main barriers which 
affected parent’s ability to have the conversation.  
It can be seen that previous research exploring the nature of disclosure in girls with TS is fairly limited. The 
issue of diagnostic disclosure was highlighted by chance through a quantitative study, and King et al., 
(2016b)’s research is similarly quantitative in nature. Although there are benefits to quantitative research, 
such as generalisability and being able to test a hypothesis (Black, 1999), qualitative methods can be 
valuable to initially develop theories around complex or under researched conditions, arguably providing a 
more holistic view (Bogdan and Taylor, 1975). Sutton et al., (2005, 2006) studies were qualitative; however, 
the primary objective was to determine the general concerns and challenges faced by girls with TS, rather 
than explore their experience of disclosure. Therefore, it could be useful to conduct further qualitative 
research to develop a richer understanding of disclosure in girls with TS. Moreover, King et al., (2016b) only 
collected data from parents/carers of girls with TS. Therefore, it could be useful to examine disclosure and 
infertility from the perspectives of girls themselves.  
Research exploring adolescents views and experiences of disclosing conditions such as autism and HIV 
found teenagers are often reluctant to tell others about their diagnosis, for fear of being treated differently or 
experiencing stigma (Humphrey, Neil and Lewis, 2008; Michaud et al., 2009). Metcalfe, Coad, Plumridge, 
Gill, & Farndon (2008) found children with genetic conditions rarely discussed the condition or its risks with 
their siblings. Most communication took place between the child and parent(s). As far as we are aware, 
there has been no prior research conducted to explore how girls with TS feel about disclosing their condition 
to others.  
Lastly, current literature has not yet explored the impact that receiving a diagnosis of TS has had on the girls 
and how the condition affects their day to day lives. It is also unclear how having a child with TS impacts 
upon parents and families.  
 
Aims: 
The primary aim of this study is to explore the nature of disclosure in girls with Turner Syndrome. It’s 
anticipated this will involve exploring at least three topics: 
1. How adolescent girls learned they had TS 
2. Parents experience of discussing and potentially disclosing aspects of TS to their children 
3. How girls with TS feel about disclosing their condition to others 
 
The secondary aim of this study is to explore whether TS has an impact on girls and their family’s lives. It is 
anticipated this will explore: 
1. The impact of having TS on the girls, for example, has it affected their relationships or self-concept  
2. The impact that having a child with TS has on families  
 
Plan of investigation 
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Participants:  
Participants will be girls diagnosed with Turner Syndrome, recruited from two designated Turner Syndrome 
clinics. The first clinic is for children and adolescents based within the Royal Hospital for Children, Glasgow. 
The number of girls that typically attend the clinic is around 40, and 8 girls in total attend each monthly clinic. 
The second clinic is based in the Area G clinics within the Queen Elizabeth University Hospital, Glasgow, 
and similarly around 40 adults typically attend. Girls’ parents/guardians will also be invited to participate. 
Girls aged over 18 years old who may not attend the clinic with a parent, will be asked to distribute Patient 
Information Sheets (PIS) to their parents/guardians inviting them to take part.  It is recognised that this is a 
relatively small sample to recruit from, however the clinical team has reassured there will be people willing 
to take part, and fully support the recruitment procedure. We are therefore confident we will reach the 
participant target. 
If we are not able recruit enough participants through the clinic, participants may be reached through 
publication of an advert in a newsletter produced by the Turner Syndrome Support Society, UK. 
No. of participants: This study aims to recruit 6-8 adolescent girls and at least one of their 
parents/guardians.  
 
Participants with TS Inclusion criteria: 
• Girls aged between 12-25 years old.  
• Received diagnosis of Turner Syndrome. 
• Have at least one parent/guardian who also wishes to take part. 
Exclusion criteria: 
• Participants with a significant learning disability. Participants who do not or did not attend main 
stream school shall not be included. 
• Participants that do not speak English.  
Parents/guardians inclusion criteria: 
• Be the parent/guardian to a girl aged between 12-25 years old diagnosed with TS. 
Exclusion criteria: 
• Participants that do not speak English.  
 
Recruitment procedures: 
Girls and their parents/guardians will be posted a PIS and Cover letter inviting them to take part. Patients 
with TS aged over 18 years old, who may not live with their parents, will also be sent the parent/guardian 
PIS sheet and shall be asked to distribute this. The lead clinician’s (Dr Mason and Dr Freel) will post the 
information. Three separate Information Sheets will be written, one for girls aged 12-15 years old, another 
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for girls aged 16-25 years old and a third for parents/guardians. As some participants are under the age of 
16, an Information Sheet that includes parental/guardian consent is necessary for informed consent.  
There shall be two ways participants can indicate consent. Firstly, the PIS will invite them to contact a 
member of the research team prior to their appointment if they would like to take part. Alternatively, the lead 
clinicians will ask all potential participants if they would like to take part when they attend the clinic. If they 
indicate they would like to take part, the researcher shall contact them to provide any further information 
required and arrange the interview. The Trainee Clinical Psychologist shall also attend both clinics to 
provide further information about the study and answer any questions from potential participants. Potential 
participants shall firstly be approached by either lead clinician and asked whether or not they wish to speak 
to the trainee.  
Two separate consent forms shall be distributed once participants have agreed with the researcher to take 
part: one for girls aged 12-15 years old and another for girls aged 16-25 years old and the 
parents/guardians. Uptake rates shall be monitored, and as we get close to 8 participants, we will be careful 
about offering additional invitations.   
 
 
Measures: 
Semi structured qualitative interviews will be conducted with both girls with Turner Syndrome and at least 
one of their parents/guardians.  
 
Design: 
This study shall be qualitative in nature, to gain a fuller insight into the nature of disclosure in girls with TS.   
 
Research procedures: 
Girls and their parents/guardians shall be initially interviewed together using a dyadic interview approach. 
Advantages of dyadic interviews include the opportunity to bring interaction into the interview (Kitzinger, 
1995) and expand the coverage of the research topic by participants sharing their point of view (D. L. 
Morgan, Eliot, Lowe, & Gorman, 2016). However, previous research indicates family members may not talk 
openly in front of one another to an interviewer if they worry about criticising or raising sensitive topics which 
could hurt another’s feelings or damage the relationship (Morris, 2001)(Corbin and Morse, 2003). It could be 
the case that girls may not respond as openly if their parents/guardians are within the same interview. A 
parent may also feel more comfortable discussing the challenges of disclosure without their child present. 
Therefore, both parties shall then be interviewed individually, unless they choose to decline.   
One interviewer shall conduct the semi structured, in-person interviews, lasting between 45-60 minutes. 
Interviews shall be conducted either directly after their appointment as part of the monthly clinic or 
scheduled for another time that suits them. Please see Appendix 1 for a draft interview schedule.  
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All interviews will be audio taped and transcribed verbatim.  
Please see Appendix 2 for a draft timetable.  
 
Data Analysis: 
Transcripts will be coded using standard qualitative research methods. Data shall be analysed using NVivo 
software. Qualitative methods considered for this study included inductive approach such as Interpretative 
phenomenological analysis (IPA) and Grounded Theory and deductive approaches such as Framework 
Analysis. The aim of IPA is to explore in detail the processes through which participants make sense of their 
own experiences, focusing on their own perceptions, understanding and views (Brocki and Wearden, 2006). 
Categories to describe and explain phenomena are derived inductively, which means they are gradually 
obtained from the data.  
Grounded theory was first described by (Glaser and Strauss, 1967), and aimed to generate a “grounded 
theory” to describe and explain the phenomenon under study. Grounded theory includes all data sources 
that might contribute to theory development such as diaries and observations, unlike IPA which uses mainly 
interviews. A literature review is carried out after collecting and analysing data, rather than before.  
Framework Analysis is deductive in its approach meaning the categories are derived at the beginning or part 
way through analysis. It is better tailored to qualitative research that is time limited, has explicit questions, 
and a pre-designed sample, for example working professionals. Framework analysis can generate theories, 
however the primary interest is to describe and interpret what is happening in a particular setting (Ritchie, J. 
& Spencer, 1994) 
IPA is the method which will be employed in this study. A systematic review from (Smith, 2011) found that 
illness experience accounted for the largest proportion of IPA research, which is unsurprising given that IPA 
was first established in Health Psychology. As this study explores patients lived experience of having a 
condition, which naturally plays a significant part in their lives and concerns of those with the condition and 
their families, IPA was decided to be the most appropriate method of analysis. Furthermore, it was 
necessary to carry out a literature review before analysis to provide the researcher with a better 
understanding of TS, and so grounded theory would have been inappropriate. Lastly, because this is a 
subject lacking in research, open-ended, explorative questions will enable richer responses from 
participants, rather than explicit questioning. Qualitative interviews will therefore be conducted as best 
practice within IPA methodology (Smith, 2009). 
All audio data shall be anonymised during transcription, and any identifiable information removed. Audio 
recordings will be stored within a locked filing cabinet in the locked Psychology Department and anonymised 
transcriptions will be stored on ‘OneDrive for Business’, one of the University of Glasgow’s secure storage 
providers, on a password protected computer. Researchers from the University of Glasgow collect, store 
and process all personal information in accordance with the General Data Protection Regulation (2018) and 
the Data Protection Act (2018). This means that it will be stored securely and not shared with other people 
without permission. If any findings from this study are published, participants identity will be anonymised. 
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The data will be stored in facilities in line with the University of Glasgow retention policy of up to 10 years 
and will not pass this information to a third party without express permission from participants. After this, 
further retention may be agreed, or the data will be securely destroyed in accordance with the relevant 
standard procedures.  
 
Justification of sample size: 
We expect that we will reach saturation of themes by interviewing 6-8 girls and at least one of their 
parents/guardians. Similar qualitative studies interviewing dyads recruited around the same number of 
participants; Akeson, Worth, & Sheikh (2007) explored the psychosocial impact of anaphylaxis on young 
people and their parent’s, interviewing seven adolescents and their parent’s. Another study explored the 
experience of having Huntingdon’s disease, interviewing seven parent/adult – child dyads jointly (Maxted, 
Simpson and Weatherhead, 2014). They similarly used IPA to analyse the resultant data. Due to the depth 
and detail of analysis and understanding of how girls and their parents/carers experience TS, a small, 
purposively selected sample will be appropriate.  
We recognise this study includes a fairly wide age range of participants. The reason for this is because the 
sample population we are recruiting from is relatively small. The study population is small because Turner 
syndrome is a rare disease; diagnosis can occur throughout childhood, adolescence or even into adulthood 
and, therefore, reducing the age range to be included would limit the size of the population from which we 
could recruit. This would impact on the study being adequately powered to answer the research question. 
Moreover, although a 12 year old's experience of having TS may be different from that of a 25 year old; this 
is not the primary focus of the research. The primary aim of this study is to explore how girls learned they 
had TS and their parents/guardians experience of discussing and potentially disclosing aspects of the 
condition. We are including girls who received their diagnosis across all time points from birth to 
adolescence. Including girls aged 12-25 may better inform the perspective of girls from early to late 
adolescence, as outlined in the study aims. We hope including a wider age range may generate a wider 
range of themes, which may be grouped together during analysis.  
 
Setting and equipment: 
Interviews will be conducted within the Royal Hospital for Children, Glasgow and the Area G clinics within 
the Queen Elizabeth University Hospital, Glasgow in a private clinic room. The equipment needed includes 
an audio recorder and interview questions.  
 
Health and safety issues 
As the topic of the interview may be sensitive for some participants, it could be the case that girls or their 
parents/guardians become distressed during the interview. If this does happen, the interviewer will ask the 
participant if they would like a break or would like to stop the interview altogether. If they would like a break, 
the audio recording shall be paused, and the researcher will ask whether they would like a moment alone, or 
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whether they would like to talk about what has caused them distress. If they are then comfortable to 
continue, the interview shall be resumed, if not the participant shall be debriefed. 
 
Dissemination 
The findings of this study shall be disseminated through the Trainee Clinical Psychologist’s doctorate thesis 
and may be submitted to a peer reviewed journal for publication. Participants will be able to read the final 
paper if it is published in a peer reviewed journal and will also be asked if they would like to read a plain 
English summary of the final report. 
 
Ethical issues  
The main ethical issues arising from this study are around consent and potential distress to participants 
caused by procedural risks. The study includes participants under the age of 16 and so it is essential all 
participants have been able to provide informed consent. It is possible a participant becomes distressed 
during their interview due to the sensitive nature of the topic discussed. The above protocol will be 
employed, and a member of the Psychology team will be made aware the interviews are taking place, in 
case anyone does become distressed and wishes to speak to another member of staff. This study shall be 
submitted for ethical approval to the NHS Greater Glasgow and Clyde Ethics Committee. Management 
approval from the Health Board R&D will also be required. 
 
Financial issues 
Costs that shall be covered will include printing (participant information sheets and consent forms) and for 
audio recording equipment. It might also be necessary to provide travel costs if participants are interviewed 
out with their usual clinic appointment at the hospital. Travel costs have been estimated at no more than £30 
per participant family group, totalling £240. This will be funded by the University of Glasgow. 
 
Practical applications 
We would hope this research project could provide further recommendations for parents and health care 
professionals about factors that facilitate disclosure of a TS diagnosis to girls. It may also highlight the 
potential barriers to parents disclosing aspects of the condition to their children and provide tools and/or 
advice to help reduce these barriers. Previous research indicates infertility can be a challenging topic for 
parents to discuss with their children and so this study could provide a greater understanding around why 
and provide practical suggestions for the way to frame this conversation. If the way in which their condition 
was disclosed to them has had any lasting impact on girls with TS, it’s essential that parents feel confident 
in talking to their children about their condition, to minimise any further distress.   
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